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Abstract 
Wei Mo 
 
Contributions of TM5, ECL3 and TM6 of human BCRP to its oligomerization 
activities and transport functions 
 
Human BCRP is one of the major ATP-binding cassette transporters 
involved in the development of multidrug resistance in cancer chemotherapy. 
Overexpression of BCRP in the tumor cell plasma membrane and apical 
membrane of the gastrointestinal tract leads to decreased intracellular 
accumulation of various anticancer drugs as well as reduced drug bioavailability. 
BCRP has been shown to exist on the plasma membrane as higher forms of 
homo-oligomers. In addition, the oligomerization domain of BCRP has been 
mapped to the carboxyl-terminal TM5-ECL3-TM6 and this truncated domain, 
when co-expressed with the full-length BCRP, displays a dominant inhibitory 
activity on BCRP function. Thus, the oligomerization of BCRP could be a 
promising target in reversing multidrug resistance mediated by BCRP.  
To further dissect the oligomerization domains of human BCRP and test 
the hypothesis that TM5, ECL3, and TM6 each plays a role in BCRP 
oligomerization and function, we engineered a series of BCRP domain-swapping 
constructs with alterations at TM5-ECL3-TM6 and further generated HEK293 cells 
stably expressing wild-type or each domain-swapping construct of BCRP. Using 
co-immunoprecipitation and chemical cross-linking, we found that TM5, ECL3, 
 vi 
and TM6 all appear to partially contribute to BCRP oligomerization, which are 
responsible for the formation of oligomeric BCRP. However, only TM5 appears to 
be a major contributor to the transport activity and drug resistance mediated by 
BCRP, while ECL3 or TM6 is insufficient for BCRP functions. Taken together, 
these findings suggest that homo-oligomeric human BCRP may be formed by the 
interactions among TM5, ECL3 and TM6, and TM5 is a crucial domain for BCRP 
functions and BCRP-mediated drug resistance. These findings may further be 
used to explore targets for therapeutic development to reverse BCRP-mediated 
drug resistance and increase the bioavailability of anti-cancer drugs for better 
treatment of multidrug resistant cancers.   
 
 
Ahmad R. Safa, Ph.D., Co-Chair of Committee 
 
 
Jian-Ting Zhang, Ph.D., Co-Chair of Committee 
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 I. Introduction 
Chemotherapy has been a major form of treatment for various cancers 
since the 1940s. However, ineffectiveness and failure of the chemotherapy with a 
single agent was soon observed. This is due to the ability of cancer cells to mutate 
spontaneously at a rate of approximately 10-7 cells per generation, acquiring 
resistance to the single agent in response to the pressures imposed by the drug 
treatment (Boesen et al., 1994). In order to resolve this issue, the break through 
concept of combination therapy was introduced into cancer chemotherapy in the 
1960s, which was based on the premise that the emergence of resistant cancer 
could be prevented with an alternating combination of drugs that have different 
intracellular targets. Nevertheless, multidrug resistance (MDR), which refers to 
the ability of organisms and cells to display resistance to a wide range of drugs 
that are structurally and functionally unrelated, has become a pervasive clinical 
phenomenon in a majority of cancers ever since the introduction of combination 
therapy. In spite of the fact that combination therapy has proved its effectiveness 
in cancers, MDR is now a major obstacle to successful cancer chemotherapy.  
Cellular and molecular mechanisms of MDR have been extensively 
examined and reviewed in detail (Gottesman et al., 1994, Gottesman et al., 2002, 
Szakacs et al., 2006, Gillet and Gottesman, 2010). Studies with drug-selected 
model cell lines have demonstrated that overexpression of certain members from 
the ATP-binding cassette (ABC) transporter superfamily, including P-glycoprotein 
(Pgp, ABCB1), multidrug resistance associated protein 1 (MRP1, ABCC1), and 
breast cancer resistance protein (BCRP, ABCG2), is one of the major 
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mechanisms involved in MDR. The increased expression of these pre-existing 
ABC transporters on plasma membranes have led to increased efflux and 
decreased intracellular concentrations of their substrates, many of them being 
anti-cancer drugs. 
The ABC transporters represent the largest family of transmembrane 
proteins. There are now 48 known human ABC transporters, and they have been 
divided into seven distinct subfamilies from ABCA through ABCG, based on gene 
structure similarities and sequence homology (Table 1). Human ABC transporters 
are exclusively exporters. They utilize the energy from ATP hydrolysis and are 
predominantly involved in the efflux of essential endogenous compounds, 
including amino acids, metabolic products, vitamins, lipids and sterols, as well as 
exogenous drugs and toxins, from the cytoplasm into the extracellular space or 
the intracellular compartments (endoplasmic reticulum, mitochondria, peroxisome, 
etc). Therefore, human ABC transporters play essential roles in a majority of 
physiological, pathological, and pharmacological processes. 
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Table 1: List of human ABC transporters. 
Name Domain structure Major functions  
ABCA subfamily 
ABCA1 MSD1-NBD1-MSD2-NBD2 Cholesterol and phospholipids efflux 
ABCA2 MSD1-NBD1-MSD2-NBD2 Drug resistance 
ABCA3 MSD1-NBD1-MSD2-NBD2 Surfactant secretion 
ABCA4 MSD1-NBD1-MSD2-NBD2 Retina-specific and efflux N-retinylidene-PE  
ABCA5 MSD1-NBD1-MSD2-NBD2 Cholesterol efflux 
ABCA6 MSD1-NBD1-MSD2-NBD2 Macrophage lipid homeostasis? 
ABCA7 MSD1-NBD1-MSD2-NBD2 Lipid homeostasis? 
ABCA8 MSD1-NBD1-MSD2-NBD2  
ABCA9 MSD1-NBD1-MSD2-NBD2 Monocyte differentiation and macrophage lipid 
homeostasis? 
ABCA10 MSD1-NBD1-MSD2-NBD2 Macrophage lipid homeostasis? 
ABCA12 MSD1-NBD1-MSD2-NBD2 Keratinocyte differentiation 
ABCA13 MSD1-NBD1-MSD2-NBD2 Susceptibility factor for schizophrenia 
ABCB subfamily 
ABCB1  MSD1-NBD1-MSD2-NBD2 MDR 
ABCB2 MSD-NBD Peptide efflux 
ABCB3 MSD-NBD Peptide efflux 
ABCB4 MSD1-NBD1-MSD2-NBD2 Phosphatidylcholine (Frank et al.) secretion 
ABCB5 MSD1-NBD1-MSD2-NBD2 Drug resistance 
ABCB6 MSD-NBD Iron efflux 
ABCB7 MSD-NBD Iron/sulfur cluster efflux 
ABCB8 MSD-NBD Drug resistance 
ABCB9 MSD-NBD Peptide efflux  
ABCB10 MSD-NBD Peptide efflux? 
ABCB11 MSD1-NBD1-MSD2-NBD2 Bile salt efflux 
ABCC subfamily 
ABCC1  MSD0-MSD1-NBD1-MSD2-NBD2 MDR 
ABCC2 MSD0-MSD1-NBD1-MSD2-NBD2 Organic anion efflux 
ABCC3 MSD0-MSD1-NBD1-MSD2-NBD2 Organic anion efflux 
ABCC4 MSD1-NBD1-MSD2-NBD2 Nucleoside efflux 
ABCC5 MSD1-NBD1-MSD2-NBD2 Nucleoside efflux 
ABCC6 MSD0-MSD1-NBD1-MSD2-NBD2 Organic anion efflux? 
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ABCC7 MSD1-NBD1-MSD2-NBD2 Chloride ion channel 
ABCC8 MSD0-MSD1-NBD1-MSD2-NBD2 K+ channel regulation 
ABCC9 MSD0-MSD1-NBD1-MSD2-NBD2 K+ channel regulation 
ABCC10 MSD0-MSD1-NBD1-MSD2-NBD2 Organic anion efflux? 
ABCC11 MSD1-NBD1-MSD2-NBD2 Drug resistance 
ABCC12 MSD1-NBD1-MSD2-NBD2 Drug resistance 
ABCD subfamily 
ABCD1 MSD-NBD Very long chain fatty acid (VLCFA) efflux 
ABCD2 MSD-NBD VLCFA and DHA metabolism 
ABCD3 MSD-NBD VLCFA metabolism? 
ABCD4 MSD-NBD VLCFA metabolism? 
ABCE subfamily 
ABCE1 NBD1-NBD2 Translation termination and ribosome recycling 
ABCF subfamily 
ABCF1 NBD1-NBD2  
ABCF2 NBD1-NBD2 Drug resistance? 
ABCF3 NBD1-NBD2  
ABCG subfamily 
ABCG1 NBD-MSD Cholesterol efflux 
ABCG2 NBD-MSD MDR 
ABCG4 NBD-MSD Cholesterol efflux 
ABCG5 NBD-MSD Sterol efflux 
ABCG8 NBD-MSD Sterol efflux 
Summarized in (Dean et al., 2001, Cascorbi and Haenisch, 2010) 
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The human breast cancer resistance protein (BCRP) is one of the human 
ABC transporters that have been implicated in the MDR in cancer chemotherapy 
(Szakacs et al., 2006). The BCRP gene was cloned independently from both 
drug-selected model cell lines and non-drug selected human cDNA library. BCRP 
cloned by Doyle’s group from the human breast cancer MCF-7/AdVp subline was 
termed BCRP for breast cancer resistance protein (Doyle et al., 1998). 
Simultaneously, Allikmets’ group searched expressed sequence tag databases 
and described a nearly identical transporter, named ABCP for its high expression 
in the placenta (Allikmets et al., 1998). Shortly after, the cDNA of this transporter 
was cloned from a mitoxantrone-selected human colon carcinoma cell line, 
S1-M1-80, and was designated MXR for mitoxantrone resistance gene 
(Maliepaard et al., 1999). This transporter was later assigned as ABCG2 by the 
Human Genome Nomenclature Committee, as a second member of the ‘G’ 
subfamily of ABC transporters.  
Human BCRP is clinically significant in prognosis of both hematopoietic 
and solid malignancies, in the development of both innate and acquired MDR, and 
in the regulation of drug bioavailability. Thus, BCRP has been considered as 
promising in targeted cancer chemotherapy, since inhibition of BCRP increases 
not only the intracellular level but also the systemic level of anti-cancer BCRP 
substrates, therefore reversing the MDR mediated by this ABC transporter 
(Robey et al., 2011).   
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A. Structure-function relationship of BCRP 
As mentioned earlier, all human ABC transporters harbor a distinctive 
feature of modular architecture, which is composed of at least one hydrophilic 
cytosolic nucleotide binding domain (NBD) and one hydrophobic 
membrane-spanning domain (MSD) (Figure 1). Based on the structure and 
arrangement of NBD and MSD, human ABC transporters can be classified into full 
transporters, half transporters and non-transporter type ABC proteins (Linton, 
2007). Typically, full ABC transporters, such as ABCB1, comprise two 
homologous halves and are characterized by two MSDs and two NBDs with an 
arrangement of MSD1-NBD1-MSD2-NBD2 (Figure 1A). Other types of full ABC 
transporters, such as ABCC1, have an extra MSD (MSD0) at the amino terminus 
with a domain structure of MSD0-MSD1-NBD1-MSD2-NBD2 (Figure 1B). On the 
other hand, some are considered as half transporters because they contain only 
one MSD and one NBD and are about half the size of a full transporter. These 
include members of the ABCD subfamily and some of the ABCB subfamily with a 
domain structure of MSD-NBD (Figure 2C), and members of the ABCG subfamily 
with a reversed NBD-MSD configuration (Figure 2D). Finally, the ABCE and 
ABCF subfamilies do not even have MSDs and they are therefore unlikely to have 
transport ability and are categorized as non-transporter type ABC proteins. The 
domain structures corresponding to each of all 48 human ABC transporters are 
listed in Table 1.  
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Figure 1: Domain structures of full and half ABC transporters. Schematic 
domain structures of full (A, B) and half (C, D) ABC transporters are shown with 
cylinders representing transmembrane segments (TM) linked by loops. The gray 
boxes represent membrane lipid bilayers. 
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In terms of function, the MSDs seem to contain substrate-binding sites and 
usually hold diverse transmembrane segments (typically six putative α-helices per 
domain), which contribute to substrate specificity. Furthermore, MSDs may form a 
pore across the membrane through which substrates move (Linton, 2007). On the 
other hand, the NBDs are highly conserved domains and represent the hallmark 
feature of the ABC transporter superfamily. In response to ATP hydrolysis 
following substrate binding, these NBDs located at the cytoplasmic face of the 
membrane undergo conformational change, which alters both the affinity and 
orientation of the substrate-binding sites (Linton and Higgins, 2007). This is widely 
accepted as the ‘ATP switch’ model powering the function of ABC transporters.   
BCRP has been widely considered as a half ABC transporter (Doyle and 
Ross, 2003), with a reversed domain structure of N-terminal NBD followed by 
C-terminal MSD (Figure 2). Several characteristic sequence motifs of ABC 
transporters have been found within the NBD of BCRP (GenBank: AAG52982.1), 
such as 80GPTGGGKSSL89, a Walker A motif (also called P–loop, GxxGxGKS/T, 
where x can be any amino acid) and 206ILFLDE211, a Walker B motif (hhhhDE, 
where h stands for hydrophobic residue) (Walker et al., 1982, Krishnamurthy and 
Schuetz, 2006). Studies of many ATPases and ABC transporters have shown that 
the lysine (K) in the Walker A motif interacts with the γ and β phosphate groups of 
ATP and is essential for ATP hydrolysis, while the aspartate (D) in the Walker B 
motif coordinates the Mg2+ ion of Mg-ATP and is required for nucleotide binding 
(Carson et al., 1995, Gribble et al., 1997). Indeed, a lysine mutant K86M in the 
Walker A motif of BCRP, when expressed in Sf9 insect cells, lost both ATP 
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hydrolytic activity and transport ability for typical BCRP substrates, including 
mitoxantrone, rhodamine 123 and Hoechst 33342 dye, though the mutant 
maintained normal protein expression level and ATP binding activity (Ozvegy et 
al., 2002), suggesting the crucial role of these highly conserved motifs in the 
catalysis of ATP hydrolysis of BCRP. Henriksen et al. further investigated the 
K86M BCRP mutant in HEK293 cells and confirmed that this mutation does not 
affect the protein expression or the dimerization/oligomerization of BCRP 
(Henriksen et al., 2005b). Instead, the K86M BCRP mutant was inactive by itself 
and also resulted in a dominant-negative effect on wild-type BCRP function. 
Moreover, distinct from the normal plasma membrane localization of wild-type 
BCRP, K86M was localized to the Golgi apparatus followed by retrieval to the 
endoplasmic reticulum (ER), indicating that NBD might play an important role in 
the proper surface trafficking of BCRP. On the other hand, mutation of the 
putative catalytic residue E211 of the Walker B motif resulted in a total loss of 
ATPase activity and ATP dependent drug transport, suggesting ATP hydrolysis is 
crucial for BCRP transport activity (Hou et al., 2009). In addition, the D210N 
mutation results in loss of function with normal protein expression and membrane 
trafficking (Bhatia et al., 2005). 
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Figure 2: Membrane topology model of BCRP. The depicted model was 
constructed on the basis of sequence analysis and the available experimental 
data. Mutations affecting substrate specificity or catalytic activity are indicated 
with red solid circles. Amino acids as part of the motifs are indicated with gray 
solid circles. Common SNPs affecting expression or function of BCRP are 
indicated with blue dashed circles. The gray boxes represent membrane lipid 
bilayers. 
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Meanwhile, the most characteristic ABC signature motif (XSXGX) 
186VSGGERKRTS195, which might be involved in nucleotide binding and 
hydrolysis or facilitating interface with the membrane-spanning domain, is located 
in the nucleotide binding domain of BCRP preceding the Walker B motif 
(Nakanishi et al., 2003a, Dawson et al., 2007). The significance of the ABC 
signature motif in BCRP function has been demonstrated (Nakanishi et al., 
2003a) in that human BCRP cRNA containing mutations of serine 187 (S187T or 
S187A) in the ABC signature motif conferred normal protein expression of BCRP 
in Xenopus laevis oocytes, but completely abolished its transport activities. 
Recently, two putative steroid-binding sites in human BCRP were identified 
through homology modeling, including the Walker A motif in the nucleotide 
binding domain (Mares-Samano et al., 2009) and a steroid-binding element 
(552SGLLVNL558) in the TM5 of BCRP (Velamakanni et al., 2008). These results 
might provide more details on the relationship of BCRP structure and substrate 
binding, as well as development of new therapeutic ligands of BCRP. 
Amino acids that are crucial for BCRP function have also been examined 
extensively. Four amino acids of BCRP, including E446 in TM2, R482 in TM3, 
N557 in TM5 and H630 in TM6, have demonstrated their contribution to the 
substrate recognition of BCRP (Miwa et al., 2003). Two other basic residues, 
H457 and R465, might also be involved in substrate binding of BCRP (Cai et al., 
2010). Several amino acids in TM5 are also functionally relevant. L554 is 
important for transport activity (Kage et al., 2002), and N557 might play an 
essential role in the proper routing and substrate binding of BCRP (Mohrmann et 
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al., 2005), while a mutant of the conserved G553 showed reduced protein 
expression, and abolished N-glysosylation and membrane trafficking of BCRP 
(Polgar et al., 2006).   
Mutation of the conserved R383 located near the cytoplasmic side of TM1 
resulted in partial retention in the ER, impaired N-glycosylation, and rapid 
degradation through the proteasome. Overall, this mutation brought about 
impairment in BCRP expression and trafficking, indicating that R383 is crucial for 
the biogenesis of BCRP (Polgar et al., 2009). A highly conserved 406GXXXG410 
motif, which has been linked with dimerization in other membrane proteins, is also 
located in the TM1 of BCRP. Mutation of both glycines to alanines maintained a 
fully functional transporter. However, mutation of glycines to leucines resulted in 
decreased transport of mitoxantrone, PhA and BODIPY-prazosin, and abolished 
transport ability for rhodamine 123, without affecting protein expression, 
membrane trafficking, basal ATPase activity or dimer formation under 
nonreducing conditions (Polgar et al., 2004). Furthermore, the combined 
mutations of GXXXG and T402, which is located in TM1 and is adjacent to the 
GXXXG motif, markedly reduced protein expression, disrupted N-glycosylation 
and membrane trafficking and promoted proteosome-independent degradation 
(Polgar et al., 2010).  
B. Dimer vs oligomer 
While the detailed molecular mechanisms of human ABC transporter 
functions remain elusive, it is widely accepted that a functional ABC transporter 
requires two MSDs coupled to two NBDs. Co-expression of both N-terminal and 
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C-terminal halves of ABCB1 in insect cells showed normal drug transport activity 
comparable to that of intact transporter, while either half expressed individually 
retained normal trafficking yet lost transport activities (Gao et al., 1996). Similar 
results observed with ABCC7 (Ostedgaard et al., 1997) and several other 
prokaryotic ABC transporters (Gauthier et al., 2003) further strengthened this 
concept. Therefore, the functional unit of full ABC transporters is believed to be a 
monomer, and half transporters require homo- or hetero-dimerization to be 
functionally competent.  
BCRP is a half transporter and was originally thought to exist and work as 
a homo-dimer. This hypothesis is supported by a study showing that 
co-expression of an ATPase-dead BCRP with the wild-type BCRP resulted in 
reduction of the BCRP transport activity and that BCRP migrated as monomers 
on SDS-PAGE under reducing conditions but as a dimer complex in the absence 
of reducing agents (Kage et al., 2002). It was also found that human BCRP 
expressed in insect cells or bacterial cells retains its function, which argues 
against the necessity of other mammalian protein partners for BCRP function 
(Ozvegy et al., 2001). Thus, it was concluded that BCRP probably exists as a 
homo-dimer linked by disulfide bonds. Attempts have been made to determine the 
cysteine residues involved in inter-molecular disulfide bond formation, and 
Cys603 in the extracellular loop 3 (ECL3) of BCRP was identified. Cys603 is not 
required for protein expression or localization, nor is it essential for ATPase 
activity or transport function of BCRP (Bhatia et al., 2005, Henriksen et al., 2005a, 
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Liu et al., 2008), suggesting that the functional BCRP does not necessarily need 
an intermolecular disulfide bridge for its function and/or oligomerization.  
However, emerging new evidence suggests that BCRP may exist as a 
higher order of oligomer on the plasma membrane. Using chemical cross-linking 
and non-reducing SDS-PAGE, Litman et al. (Litman et al., 2002) first detected 
both an apparent BCRP dimer and higher forms of oligomers from whole cell 
lysate. Similar methods used by Bhatia’s group (Bhatia et al., 2005) demonstrated 
the presence of higher order oligomers of BCRP in both isolated cell membranes 
and whole cell preparations. Recently, using various biochemical methods such 
as non-denaturing PAGE, perfluoro-octanoic acid-PAGE (PFO-PAGE), gel 
filtration chromatography, sucrose gradient sedimentation, chemical cross-linking 
as well as co-immunoprecipitation, Xu et al. (Xu et al., 2004) demonstrated that 
the major oligomeric unit of human BCRP in plasma membranes of the 
drug-resistant cell line MCF7/AdVp3000 is a homo-dodecamer with the minimum 
stable unit of homo-tetramer. No monomeric or dimeric BCRP was found under 
non-denaturing conditions, suggesting that the major functional form of BCRP 
may be a homo-oligomer. Later, the examination of purified human BCRP using 
cryo-negative staining electron microscopy showed that purified human BCRP 
may exist as a homo-octomer consisting of four homo-dimeric BCRP complexes 
(McDevitt et al., 2006). It has also been reported that the purified BCRP in the 
presence of all solubilized membrane components is a tetrameric complex when 
expressed in Sf9 cells (Dezi et al., 2010). Although the causes for the discrepancy 
among the latter three studies are unknown, it is clear that all studies have 
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demonstrated the presence of higher order oligomeric BCRP complexes. Using 
deletion mapping and co-immunoprecipitation of differential epitope tagging of 
BCRP, Xu et al. (Xu et al., 2007) discovered that the oligomerization domain of 
human BCRP is located in the MSD, consisting of ECL3 with its flanking 
transmembrane segments (TM5 and TM6). The polypeptide consisting of 
TM5-ECL3-TM6 not only forms a homo-dodecamer complex itself but also exerts 
a dominant negative effect on wild-type BCRP drug transport function and drug 
resistance phenotypes, possibly by forming hetero-complexes with the wild-type 
BCRP. It is postulated that three different inter-molecular contacts are responsible 
for the formation of a homo-dodecamer (Xu et al., 2004, Xu et al., 2007), which 
will be further tested in the current study.  
C. Substrates of BCRP and its variants 
The substrates of BCRP, identified directly by cellular or vesicular transport 
assays, or indirectly by substrate-stimulated ATPase activity or cytotoxicity 
assays, comprise a broad spectrum of anticancer drugs, sulfate and glucuronide 
conjugates of sterols and xenobiotics, natural compounds and toxins, 
fluorescence dyes, photosensitizers, antibiotics, etc (a comprehensive list of 
BCRP substrates is in Table 2).  
Among the major groups of BCRP substrates are anticancer drugs, 
including topoisomerase inhibitors, anthracyclines, camptothecin (CPT) analogs, 
tyrosine kinase inhibitors (TKI), and antimetabolites, which have identified BCRP 
as essential for MDR in cancer chemotherapy. BCRP transports many sulfate and 
glucuronide conjugates of steroids and xenobiotics, which are two common 
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products of mammalian Phase II metabolism, suggesting that BCRP is involved in 
drug metabolism. BCRP also mediates the efflux of Pheophorbide a (PhA) (Robey 
et al., 2004) and many other photosensitizers (Robey et al., 2005), implicating 
BCRP as a possible cause for photodynamic therapy resistance. BCRP is also 
involved in the transport of Abeta(1-40) peptides at the blood-brain barrier, and 
upregulation of BCRP is correlated with Abeta deposition in cerebral vessels, 
leading to cerebral amyloid angiopathy in many Alzheimer’s disease patients 
(Xiong et al., 2009). 
Studies of CPT analogs as BCRP substrates have revealed that the polar 
groups, especially hydroxyl groups, at the 9 or 10 position of the CPT A ring 
facilitate interaction with BCRP, and this information could be used to design 
BCRP insensitive CPT analogues. Also, hydrogen bond formation might be 
involved in the substrate recognition of BCRP (Rajendra et al., 2003, Ishikawa et 
al., 2006, Nakagawa et al., 2006). Additional analysis of CPT analogue structures 
strongly suggests that high-polarity CPT analogues are good BCRP substrates, 
while the low-polarity counterparts, as poor BCRP substrates, could be 
considered as BCRP insensitive compounds (Yoshikawa et al., 2004). From this 
aspect, modification of BCRP substrates could also be considered as a practical 
approach to overcome the drug resistance mediated by BCRP.   
Interestingly, in early studies with the MCF-7/AdVp3000 or 
mitoxantrone-selected S1-M1-80 cell lines, transport of rhodamine 123 was 
observed (Litman et al., 2000). However, the transport ability of rhodamine 123 
was not seen in several other BCRP overexpressing cell lines (Honjo et al., 2001). 
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This inconsistency has led to sequencing of the BCRP gene comparing a series of 
parental and BCRP overexpressing cells, and it was revealed that cells able to 
transport rhodamine 123 had a glycine (G) or threonine (T) at position 482 in the 
BCRP protein, while cells expressing wild-type BCRP with an arginine (R) at this 
site could not transport rhodamine 123. Both mutants and wild-type BCRP were 
able to efflux mitoxantrone, topotecan, SN-38, Hoechst 33342 (Ozvegy et al., 
2002) and BODIPY-prazosin (Robey et al., 2003). However, the 482G/T mutant 
has a higher affinity for anthracyclines, including doxorubicin, daunorubicin, 
epirubicin, as well as bisantrene, fluorescence dye rhodamine 123 and 
lysotracker green (Robey et al., 2003). In contrast, 482R is specific for transport of 
methotrexate (MTX) (Volk et al., 2000, Volk et al., 2002), MTX diglutamate and 
triglutamate, as well as folic acid (Chen et al., 2003). These data suggest that 
amino acid 482 might be a ‘hot spot’ for substrate specificity of BCRP.  
Nevertheless, a study using IAARh123, the photoreactive analogue of 
rhodamine 123, has surprisingly shown that both 482R and 482T bind directly to 
IAARh123. 482R could not transport IAARh123, even though it is photolabelled 
more intensely than 482T, indicating higher binding affinity of 482R to IAARh123 
(Alqawi et al., 2004). This piece of data not only provides evidence of the direct 
binding of substrates to BCRP, but also indicates that an unknown mechanism 
leads to the difference between 482R and 482T, other than substrate specificity. 
Indeed, a follow-up study, in which nine 482R mutants were generated and 
expressed in insect cells, has further demonstrated that amino acid substitution at 
position 482 induces major changes in not only substrate specificity but also the 
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transport activity of BCRP (Ozvegy-Laczka et al., 2005). 482R might also play an 
important role in ATP hydrolysis of BCRP, as demonstrated by basal and 
stimulated ATPase activity and photoaffinity labeling analyses (Ejendal et al., 
2006). Finally, compared to 482R, purified BCRP 482T exhibited an increased 
ATP hydrolysis rate and affinity for MgATP, as well as decreased sensitivity to 
vanadate inhibition and preferred binding to ATP, while substrate binding is 
similar between 482R and 482T (Pozza et al., 2006). Although mutations at 
position 482 have not been found in any clinical samples (Honjo et al., 2002, 
Nakanishi et al., 2003b, Zamber et al., 2003), 482 R does provide a superior tool 
to explore BCRP functions and to assist the modification of BCRP substrates and 
the development of BCRP inhibitors.  
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Table 2: Summary of BCRP substrates.  
Substrates Reference  
Topoisomerase inhibitors  
Mitoxantrone (topoisomerase II inhibitor) (Doyle and Ross, 2003) 
Bisantrene (topoisomerase II inhibitor) (Litman et al., 2000) 
Etoposide (topoisomeriase II inihibitor) (Yuan et al., 2009) 
Becatecarin (topoisomerase II inhibitor) (Robey et al., 2009) 
NB-506, J-107088 (topoisomerase I inhibitors) (Komatani et al., 2001) 
Anthracyclines (Topoisomerase II inhibitors)  
Daunorubicin  (Ozvegy et al., 2001) 
Doxorubicin (Adriamycin) (Ozvegy et al., 2001) 
Epirubicin  (Robey et al., 2003) 
Pirarubicin  (Yuan et al., 2009) 
Camptothecin analogs (Topoisomerase I inhibitors)   
Topotecan  (Maliepaard et al., 1999) 
SN-38 (Maliepaard et al., 1999) 
CPT-11 (Maliepaard et al., 2001b) 
9-aminocamptothecin (Maliepaard et al., 2001b) 
NX211 (Maliepaard et al., 2001b) 
DX-8951f (van Hattum et al., 2002) 
Homocamptothecins   (Bates et al., 2004) 
BN80915 (diflomotecan) (Bates et al., 2004) 
Gimatecan  (Marchetti et al., 2007) 
Belotecan  (Li et al., 2008) 
Tyrosine kinase inhibitors  
Gefitinib  (Elkind et al., 2005) 
Dasatinib  (Hiwase et al., 2008) 
Erlotinib  (Marchetti et al., 2008) 
Vandetanib (Azzariti et al., 2010) 
Nilotinib  (Hegedus et al., 2009) 
Sorafenib  (Agarwal et al., 2011) 
Tandutinib  (Yang et al., 2010) 
CI1033 (Pan-HER TKI) (Erlichman et al., 2001) 
CP-724,714 (HER2 TKI) (Feng et al., 2009) 
Symadex (fms-like tyrosine kinase 3 inhibitor) (Bram et al., 2009) 
Antimetabolites   
MTX, MTX diglutamate, MTX triglutamate (antifolate) (Chen et al., 2003) 
GW1843, Tomudex (antifolates) (Shafran et al., 2005) 
Trimetrexatte, piritrexim, metoprine, pyrimethamine 
(lipophilic antifolates)* 
(Bram et al., 2006) 
5-fluorouracil (pyrimidine analog) (Yuan et al., 2009) 
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CdAMP (nucleotide), cladribine (nucleoside) (de Wolf et al., 2008) 
Other anticancer drugs  
Flavopiridol (cyclin-dependent kinase inhibitor) (Nakanishi et al., 2003b) 
JNJ-7706621 (CDK and aurora kinases inhibitor) (Seamon et al., 2006) 
Bicalutamide (non-steroidal anti-androgen) (Colabufo et al., 2008) 
NSC73306 (Wu et al., 2007) 
Phenethyl isothiocyanate (PEITC) (Ji and Morris, 2004) 
TH-337 (indazole-based tubulin inhibitors) (Meng et al., 2008) 
Sulfate and glucuronide conjugates of xenobiotics  
Estrone 3-sulfate (E1S) (Suzuki et al., 2003) 
17beta-estradiol sulfate (Imai et al., 2003) 
DHEAS (Suzuki et al., 2003) 
4[35S]-methylumbelliferone sulfate (Suzuki et al., 2003) 
E3040 sulfate (Suzuki et al., 2003) 
Troglitazone sulfate (Enokizono et al., 2007) 
3-O-sulfate conjugate of 17alpha-ethinylestradiol (Han et al., 2010) 
SN-38-glucuronide (Nakatomi et al., 2001) 
[3H]17beta-estradiol-17beta-D-glucuronide (Suzuki et al., 2003) 
[14C]4-methylumbelliferone glucuronide (Suzuki et al., 2003) 
BP-3-sulfate and BP-3-glucuronide (Ebert et al., 2005) 
Phenolic MPA glucuronide (Miura et al., 2008) 
Photosensitizers  
Pheophorbide a (Robey et al., 2004) 
Pyropheophorbide a methyl ester (Robey et al., 2005) 
Chlorine E6 (Robey et al., 2005) 
5-aminolevulinic acid (Robey et al., 2005) 
Phytoporphyrin  (Robey et al., 2006) 
HPPH (Zheng et al., 2009) 
Natural compounds and toxins  
Folic acid  (Chen et al., 2003) 
Urate  (Woodward et al., 2009) 
Genistein (Imai et al., 2004) 
Riboflavin (vitamin B2) (van Herwaarden et al., 2007) 
Vitamin K3, plumbagin (Shukla et al., 2007) 
Glutathione (GSH) (Brechbuhl et al., 2009) 
Sphingosine 1-phosphate (Takabe et al., 2010) 
PhIP (carcinogen) (Pavek et al., 2005) 
PPIX (heme precursor) (Zhou et al., 2005a) 
Fluorescent dyes  
Rhodamine 123 (Litman et al., 2000) 
IAARh123 (Alqawi et al., 2004) 
 21 
Hoechst 33342 (Ozvegy et al., 2002) 
Lysotracker green (Robey et al., 2003) 
BODIPY-prazosin (Cygalova et al., 2009) 
D-luciferin (firefly luciferase substrate) (Zhang et al., 2009) 
Cholyl-L-lysyl-fluorescein (fluorescent bile salt derivative) (de Waart et al., 2010) 
BODIPY-FL-dihydropyridine (Shukla et al., 2006) 
Others  
[(125)I]lodoarylazidoprazosin (IAAP), [(3)H]azidopine (Shukla et al., 2006) 
Sulfasalazine (anti-inflammatory) (van der Heijden et al., 2004) 
Erythromycin (macrolide antibiotic) (Janvilisri et al., 2005) 
Ciprofloxacin, ofloxacin, norfloxacin,enrofloxacin, 
grepafloxacin, ulifloxacin (fluoroquinolone antibiotics) 
(Merino et al., 2006, Pulido et 
al., 2006, Ando et al., 2007) 
Nitrofurantoin (urinary tract antibiotic) (Merino et al., 2005b) 
Moxidectin (parasiticide) (Perez et al., 2009) 
Albendazole suloxide and oxfendazole (anthelmintics) (Merino et al., 2005a) 
Ganciclovir (antiviral drug) (Hu and Liu, 2010) 
Zidovudine (NRTI) (Wang et al., 2003) 
Lamivudine (NRTI) (Kim et al., 2007) 
Leflunomide and A771726 (antirheumatic drugs) (Kis et al., 2009) 
Diclofenac (analgesic and anti-inflammatory drug) (Lagas et al., 2009) 
Cimetidine (histamine H2-receptor antagonist) (Pavek et al., 2005) 
ME3277 (hydrophilic glycoprotein IIb/IIIa antagonist) (Kondo et al., 2005) 
Pitavastatin (HMG-CoA reductase inhibitor) (Hirano et al., 2005) 
Rosuvastatin (HMG-CoA reductase inhibitor) (Huang et al., 2006) 
Dipyridamole (thromboxane synthase inhibitor) (Zhang et al., 2005) 
Glyburide (hypoglycemic agent) (Gedeon et al., 2008) 
Nicardipine, nifedipine, nitrendipine (Ca2+ channel blocker) (Shukla et al., 2006) 
Olmesartan medoxomil (angiotensin II AT1-R antagonist) (Yamada et al., 2007) 
Befloxatone (selective monoamine oxidase inhibitor) (Tournier et al., 2011) 
Prazosin (alpha-1-adrenergic receptor antagonist) (Litman et al., 2000) 
Riluzole (Na+ channel blocker) (Milane et al., 2009) 
Amyloid-beta (Tai et al., 2009) 
Zoledronic acid (osteotropic compound) (Kars et al., 2007) 
Hesperetin conjugates (flavonoid) (Brand et al., 2008) 
Kaempferol (flavonoid) (An et al., 2011) 
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D. Physiological significance of BCRP 
The substrate spectrum and the tissue distribution of BCRP have 
implicated a key role of this transporter in the protection of the human body 
against xenobiotics. In human tissues, BCRP is prominently expressed in 
placental syncytiotrophoblasts, in the epithelium of the small intestine and colon, 
in the liver canalicular membrane, and in ducts and lobules of the breast 
(Maliepaard et al., 2001a). BCRP expression has also been detected in the 
luminal membrane of epithelial cells in normal gallbladders (Aust et al., 2004), in 
alveolar pneumocytes, sebaceous glands, interstitial cells of the testes, prostate 
epithelium, endocervical cells of the uterus, squamous epithelium of the cervix, 
islet and acinar cells of the pancreas, the zona reticularis layer of the adrenal 
gland, kidney cortical tubules, and hepatocytes (Fetsch et al., 2006, Huls et al., 
2008). BCRP is also present in venous and capillary endothelium. Furthermore, 
BCRP is predominantly localized on the plasma membrane of certain cell types of 
the above tissues (Rocchi et al., 2000), many of which harbor a secretory or 
barrier function, and this specific distribution profile is closely related to the 
physiological role of human BCRP. More importantly, BCRP is highly expressed 
in various stem cells and serves as an important determinant of the side 
population (SP) phenotype (Zhou et al., 2001). 
1. BCRP as first line defense in the GI tract 
Human BCRP is physiologically expressed in the apical membrane of 
epithelial cells in the gastrointestinal (GI) tract, with maximal expression in the 
duodenum and a gradual decrease along the GI tract to the rectum (Gutmann et 
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al., 2005). BCRP is also constitutively expressed in the liver canalicular 
membranes, which supports a possible protective role of BCRP against 
xenobiotic absorption and towards toxic metabolite excretion. It has been shown 
that administration of GF120918, a dual inhibitor of ABCB1 and BCRP, resulted in 
a significant increase in the bioavailability and systemic concentration of 
topotecan after oral administration (Kruijtzer et al., 2002). Moreover, it is also 
reported that GF120918 could markedly reduce the biliary and renal excretion of 
topotecan after intravenous administration. Considering that topotecan has higher 
affinity for BCRP than with ABCB1, inhibition of BCRP by GF120918 is likely the 
major mechanism responsible for the increased intestinal absorption and 
decreased biliary and renal excretion.  
In addition, data collected from Bcrp-null mice help to appreciate this first 
line defense role of BCRP. Bcrp-null mice are more susceptible to phototoxic skin 
lesions, which are caused by accumulation of pheophorbide a, a chlorophyll 
degradation product found in food and supplements. This has implicated that 
BCRP is crucial in protecting the human body from the development of 
protoporphyria and food-related phototoxicity (Jonker et al., 2002). Meanwhile, 
BCRP is responsible for the efflux of sulfate and glucuronide conjugates of 
xenobiotics and hormones, which are mostly products of phase II metabolism, 
suggesting that BCRP has a major role in extruding toxic metabolites, mostly 
through the biliary pathway (Dietrich et al., 2003). 
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2. BCRP in the blood-brain barrier 
BCRP is constitutively expressed at the blood-brain barrier, mainly at the 
luminal cell surface of microvessel endothelium, and serves as a crucial barrier to 
drug access into the brain (Cooray et al., 2002, Zhang et al., 2003, Aronica et al., 
2005). Indeed, BCRP works with ABCB1 in the blood-brain barrier and is 
responsible for restricting numerous xenobiotics from entering the brain. The 
positive impact is that BCRP protects the brain from the toxicity of xenobiotics, 
while the negative impact is that BCRP impedes therapeutic agents from reaching 
their intracerebral targets. 
3. BCRP in the placenta 
BCRP expression is highest on the plasma membrane of the chorionic villi 
in the placenta (Litman et al., 2002). This cellular localization indicates that BCRP 
plays a major role in protecting the fetus against toxic compounds ingested by the 
mother. In Bcrp-null mice, the fetal exposure to topotecan and other dietary toxins 
increased significantly (Jonker et al., 2000), further confirming the protecting role 
of BCRP in the placenta. 
4. BCRP in stem cells 
A fascinating property of hematopoietic stem cells is their ability to actively 
extrude Hoechst 33342, a fluorescent dye. The low Hoechst 33342 staining cells 
isolated by subsequent fluorescence-activated cell sorting (FACS) are termed as 
‘side population’ (SP) (Goodell et al., 1996), which have been shown to possess 
stem cell-like characteristics in a variety of tissues (Zhou et al., 2001, Bunting, 
2002, Lechner et al., 2002, Summer et al., 2003). BCRP is expressed at a higher 
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level in SP cells, compared to non-SP cells, and has been identified as the 
Hoechst 33342 efflux pump in SP (Kim et al., 2002, Scharenberg et al., 2002). 
Moreover, ectopic expression of BCRP conferred a SP phenotype in HEK293 
cells, indicating that BCRP might serve as an attractive candidate marker for stem 
cells (Scharenberg et al., 2002). On the other hand, BCRP is expressed 
differentiational during hematopoiesis, with the highest levels in the primitive bone 
marrow stem cell populations, followed by a sharp reduction in response to stem 
cell differentiation, suggesting possible dual roles of BCRP in maintaining human 
pluripotent stem cells in an undifferentiated state, and in protecting these stem 
cells from xenobiotics or other toxins in vivo. (Zhou et al., 2001, Bunting, 2002, 
Scharenberg et al., 2002).  
Studies with Bcrp-null mice further confirmed that BCRP is necessary for 
the SP phenotype, since loss of Bcrp expression resulted in a drastic decrease in 
SP cells in the bone marrow and skeletal muscle. Notably, it has also been shown 
that the hematopoietic cells of Bcrp-null mice became more sensitive to the 
cytotoxicity of mitoxantrone, confirming the physiological protection function of 
Bcrp in hematopoietic cells (Zhou et al., 2002).  
E. Pathophysiological significance of BCRP  
Although human BCRP is widely expressed in normal tissues, 
overexpression of BCRP has been found frequently in various drug-selected 
cancer cell lines, and contributes to the clinical MDR of hematopoietic 
malignancies and solid tumors. Increased BCRP expression has also been linked 
to cancer stem cells.  
 26 
1. BCRP in MDR 
As mentioned earlier, BCRP was originally cloned from an Adriamycin 
selected breast cancer cell line MCF-7/AdVp, which exhibited resistance to a 
range of cytotoxic agents, including mitoxantrone, doxobucibin and daunorubicin, 
but had no increased expression of ABCB1 (Doyle et al., 1998). Overexpression 
of BCRP has been found in and correlated to the MDR phenotypes of numerous 
drug-selected cancer cell lines derived from various tumor types, including 
topotecan-selected ovarian tumor cell line T8 (Maliepaard et al., 1999), 
mitoxantrone-selected colon cancer cell line S1-M1-80 (Litman et al., 2000) and 
HT29 (Perego et al., 2001), SN-38-selected human small cell lung cancer (SCLC) 
cells PC-6/SN2-5 (Kawabata et al., 2001), mitoxantrone-selected human gastric 
carcinoma cell line EPG85-257RNOV (Stein et al., 2002), gefitinib-resistant 
non-small cell lung cancer (NSCLC) cells (Nagashima et al., 2006), 
epirubicin-resistant human hepatocyte carcinoma cells HLE-EPI (Kamiyama et 
al., 2006), and topotecan and doxorubicin selected human multiple myeloma cells 
(Turner et al., 2006). However, the BCRP-mediated drug resistance profiles found 
in these cell lines vary, which might be attributed to different cell origin or the 
involvement of other resistance factors, including other MDR ABC transporters, 
drug metabolizing enzymes, DNA repair, and apoptosis (Jaeger, 2009). 
Therefore, a complex model is required for better evaluation of MDR in cell lines.  
A recent approach by Szakacs et al. (Szakacs et al., 2004) has profiled 
mRNA expressions of the 48 known human ABC transporters and their correlation 
with the growth inhibition of 1,429 anticancer drug candidates in 60 diverse 
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cancer cell lines (the NCI-60). The results could more accurately predict which 
transporters are more likely related to resistance to a certain drug tested. This 
group further designed a microarray platform, the ABC-ToxChip, to evaluate the 
transcriptional profiles of a comprehensive set of genes involved in MDR between 
parental and drug-selected cell lines (Annereau et al., 2004). The sensitivity and 
accuracy of this method has been confirmed by quantitative reverse 
transcription-polymerase chain reaction (RT-PCR) and immunohistochemistry 
(IHC), suggesting that this microarray could serve as a helpful tool to clarify ABC 
transporters and other mechanisms responsible for MDR. 
2. BCRP in hematopoietic malignancies 
Although cellular models are powerful tools to examine the MDR 
phenotypes mediated by BCRP, the clinical relevance of BCRP in human cancers 
was mainly established in clinical samples. There has been considerable 
evidence demonstrating overexpression of BCRP in many different hematopoietic 
malignancies since its discovery. Early studies by Ross et al. have indicated 
relatively high levels of BCRP expression in 33% of acute myeloid leukemia 
(AML) blast cells (Ross et al., 2000). However, the contribution of BCRP for drug 
resistance or drug response in AML patients is so far inconclusive (Table 3). It 
was reported that BCRP expression could predict a decrease in complete 
remission as well as 4-year overall survival in AML patients with daunorubicin or 
mitoxantrone treatment (Benderra et al., 2004). Also, another study in AML 
patients of older age has demonstrated the relationship between higher 
Pgp/BCRP co-expression with lower complete response rate and overall survival 
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rate (van den Heuvel-Eibrink et al., 2007). In addition, Benderra et al. have shown 
that AML patients expressing one or none of functional ABCB1, ABCC3 or BCRP 
have a better prognosis than those patients expressing two or all of the above 
transporters (Benderra et al., 2005). These data suggest that modulation of all 
susceptible ABC transporters may provide therapeutic synergy and promote a 
better prognosis.  
The role of BCRP expression in acute lymphocytic leukemia (ALL) has also 
been implicated but stays inconclusive. Suvannasankha’s group has reported a 
correlation between BCRP expression and prognosis in adult ALL patients 
(Suvannasankha et al., 2004) while several other groups did not find such a 
relationship between BCRP expression and response in childhood ALL 
(Sauerbrey et al., 2002). One explanation for the discordance might be the 
different experimental methods used, different antidies used or different criteria 
for samples (adult or childhood) used (Table 3). It might also be necessary to 
expand the sample size. There is still a lot of work to be done in order to clarify the 
role of BCRP in drug resistance in hematopoietic malignancies. 
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Table 3: BCRP expression in human hematopoietic malignancies. 
Type Correlation Methods Size Reference 
AML Yes RT-PCR 20 (Ross et al., 2000) 
AML 
No 
(mitoxantrone, topotecan or 
doxorubicin based therapy) 
ICC (BXP34) 20 (Sargent et al., 2001) 
AML 
Yes 
(daunorubicin based therapy) 
ICC (BXP34) 20 (Sargent et al., 2001) 
AML No FCM (BXP34 & BXP21) 20 
(van der Kolk et al., 
2002) 
AML 
Yes 
(relapse/refractory) 
RT-PCR 20 
(van den 
Heuvel-Eibrink et al., 
2002) 
AML 
(child) 
Yes 
(prognosis, relapse) 
RT-PCR 59 (Steinbach et al., 2002) 
AML 
(adult) 
no RT-PCR 40 (Abbott et al., 2002) 
AML no RT-PCR 51 (Galimberti et al., 2004) 
AML 
adult) 
Yes 
(prognosis on daunorubicin 
and mitoxantrone therapy) 
RT-PCR 149 (Benderra et al., 2004) 
AML 
(adult) 
Yes 
(complete remission, DFS, 
overall survival) 
FCM 
(BXP21) 85 (Benderra et al., 2005) 
AML 
Yes 
(relapse and DFS) 
FCM 
(BXP34) 73 (Damiani et al., 2006) 
AML 
Yes 
(complete response rate) 
RT-PCR 154 
(van den 
Heuvel-Eibrink et al., 
2007) 
AML 
Yes 
(DFS, relapse, overall survival 
to fludarabine-based therapy) 
RT-PCR 138 (Damiani et al., 2010) 
ALL 
(child) 
No 
(prognosis) 
RT-PCR 67 (Sauerbrey et al., 2002) 
ALL Yes FCM (BXP34) 46 
(Plasschaert et al., 
2003) 
ALL 
(adult) 
Yes 
(DFS) 
ICC (BXP21) 30 (Suvannasankha et al., 2004) 
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3. BCRP in solid tumors 
Recently, correlations between BCRP expression with solid tumors have 
been reported (Table 4). In Diestra’s study, a total of 150 untreated tumor 
samples from various origins were examined, and increased expression of BCRP 
was found in tumors from the digestive tract, endometrium, lung, as well as 
melanoma (Diestra et al., 2002). In breast cancer patients, BCRP expression is 
also found to correlate with response to anthracycline-based chemotherapy 
(Burger et al., 2003). Increased BCRP expression is also related to loss of 
differentiation and shorter survival in oral squamous cell carcinomas (Friedrich et 
al., 2004). In contrast, various other studies indicate that there was no relationship 
between BCRP expression and response in breast cancer (Kanzaki et al., 2001), 
advanced bladder tumors (Diestra et al., 2003) or testicular germ cell cancers 
(Zurita et al., 2003), which strongly calls for validated assays and longitudinal 
studies to definitively assess the contribution of BCRP to drug resistance in solid 
tumors. Interestingly, Gupta et al. reported reduction of BCRP mRNA and protein 
in colorectal and cervical cancer tissues (Gupta et al., 2006). This observation 
implies that BCRP may play a role in tumorigenesis in several cancer types, 
where reduction of BCRP permits the accumulation of genotoxins or other 
carcinogenic cytokines.  
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Table 4: BCRP expression in human solid tumors. 
Type Correlation Methods Size Reference 
Breast carcinoma 
No 
(doxorubicin-based treatment) 
RT-PCR 43 (Kanzaki et al., 2001) 
Breast carcinoma 
No 
(anthracycline-based therapy) 
IHC  
(BXP21 & BXP34) 
52 (Faneyte et al., 2002) 
Breast cancer 
Yes 
(anthracycline-based therapy) 
RT-PCR 59 (Burger et al., 2003) 
Digestive tract 
tumors Yes 
IHC  
(BXP21) 
32 (Diestra et al., 2002) 
Colorectal and 
cervical cancer 
Yes 
(downregulation) 
IHC 154 (Gupta et al., 2006) 
Endometrial 
carcinoma Yes 
IHC  
(BXP21) 
5 (Diestra et al., 2002) 
Lung tumors Yes 
IHC  
(BXP21) 
10 (Diestra et al., 2002) 
NSCLC 
Yes 
(PFS and overall survival to 
platinum-based therapy) 
IHC  
(BXP21) 72 
(Yoh et al., 
2004) 
NSCLC 
Yes 
(short survival to 
cisplatin-based therapy) 
IHC  
(BXP21) 
156 (Ota et al., 2009) 
SCLC 
Yes 
(response and PFS to 
platinum-based therapy) 
IHC  
(BXP21) 
130 (Kim et al., 2009b) 
Melanoma yes 
IHC  
(BXP21) 
5 (Diestra et al., 2002) 
Melanoma no RT-PCR 18 (Deichmann et al., 2005) 
Retinoblastoma 
Yes  
(invasion) 
IHC  
(5D3) 
39 (Mohan et al., 2006) 
Retinoblastoma No 
IHC  
(BXP21) 
18 (Wilson et al., 2006) 
Esophageal 
carcinoma Yes RT-PCR 100 
(Tsunoda et 
al., 2006) 
T/NK-cell 
lymphoma Yes IHC 45 
(Saglam et 
al., 2008) 
Diffuse large 
B-cell lymphoma 
Yes  
(prognosis) 
IHC (BXP21) 67 (Kim et al., 2009a) 
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F. Regulation of BCRP expression 
Increased expression of BCRP is frequently seen in both drug resistant 
cancer cell lines and clinical tumor tissues. Numerous studies have demonstrated 
that the regulation of BCRP expression occurs at several levels, including gene 
amplification, transcriptional, posttranscriptional and epigenetic modifications.  
1. Gene amplification of BCRP 
The amplification of the BCRP gene was first reported in a variety of drug 
resistant human cancer cell lines selected by mitoxantrone (Ross et al., 1999). 
Knutsen et al. verified this phenomenon and also demonstrated chromosome 
translocation in two mitoxantrone-resistant sublines of human breast cancer cell 
line, MCF-7 AdVp3000 and MCF-7 MX, by both comparative genomic 
hybridization (CGH) and Southern blot (Knutsen et al., 2000). The 
mitoxantrone-sensitive parental cell line MCF-7, on the other hand, had no copy 
number amplification or chromosome translocation of the BCRP gene. In addition, 
it has also been shown that the resistance level to SN-38 in colorectal cancer cells 
was positively correlated to BCRP gene amplification, which resulted in a marked 
decrease in the intracellular concentration of SN-38 (Candeil et al., 2004). 
Later, Knutsen’s group extended the study to investigate the mechanisms 
of BCRP gene amplification (Rao et al., 2005). SF295 glioblastoma cells were 
exposed to an increasing concentration of mitoxantrone and four sublines with 
increasing resistance to mitoxantone, named as SF295 MX50, MX100, MX250, 
and MX500, were generated. Southern blot analysis confirmed gene amplification 
in all mitoxantrone-resistant SF295 sublines. Furthermore, fluorescence in situ 
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hybridization (FISH) demonstrated that with low levels of drug selection (MX50 
and MX100), amplification of the BCRP gene was via double minute 
chromosomes (dmins). With higher levels of drug selection (MX250 and MX500), 
BCRP gene amplification was conferred more by homogeneously staining regions 
(hsr) than by double minute chromosomes. These results indicate that BCRP 
gene amplification under drug selection probably occurred initially as double 
minute chromosomes and switched to chromosomal reintegration of the amplicon 
at multiple chromosomes to generate a more stable genotype.  
2. Transcriptional regulation of BCRP 
The human BCRP gene is located on chromosome 4q22 and spans more 
than 66 kbp (Knutsen et al., 2000). It contains 16 exons and 15 introns, which 
encode a membrane protein of 655 amino acids (Kanzaki et al., 2002). The first 
exon contains most of the 5’-untranslated region (5’-UTR) of the BCRP gene, 
while the translational start site is located in exon 2. The BCRP gene has a 
TATA-less promoter with its basal promoter activity conferred by the sequence 
312 bp directly upstream from the transcriptional start site. A CCAAT box is 
present in -274 bp and removal of this CCAAT box reduces the transcription 
acitivity of the BCRP gene. There are five putative Sp1 sites downstream from a 
putative CpG island, which is a common feature of promoters lacking a TATA box. 
It is found that the homeobox gene MSX2 recruits SP1 to the Sp1 binding sites 
within BCRP promoter and upregulates BCRP gene transcription in pancreatic 
cancer cells (Hamada et al., 2011). 
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To date, six major transcription regulation pathways, including alternative 
promoters, estrogen receptor alpha (ERα), hypoxia-inducible factor 1 (HIF-1), 
peroxisome proliferator-activated receptor gamma (PPARγ), progesterone 
receptor (PGR) and aryl hydrocarbon receptor (AHR), have been identified to 
regulate BCRP mRNA expression.  
The 5’-UTR of BCRP mRNA in cell lines highly expressing BCRP have 
been examined and compared to normal tissues. At least three forms of the 
untranslated exon 1 (E1a, E1b, E1c) with a common exon 2 were revealed, 
suggesting the existence of alternative promoters of BCRP. These exon 1 
variants present tissue-specific expression, while E1c seems to be translated 
more efficiently than E1a (Nakanishi et al., 2006).  
Sequence analysis of the 5'-flanking region of the BCRP gene has led to 
the discovery of a putative estrogen response element (ERE) between the -188 to 
-172 bp of the BCRP promoter (Ee et al., 2004b). Deletion and site-directed 
mutagenic analysis confirmed the existence of ERE in the region between -243 
and -115 bp. It has been further demonstrated that 17β-estradiol (E2) could 
promote the mRNA expression of BCRP, through activation of estrogen receptor 
alpha (ERα), which directly binds to the ERE located in the BCRP promoter. 
Using a genome-wide analysis of promoter elements for transcription factor 
binding sites, Kamalakaran et al. validated that BCRP promoter does carry a 
functional ERE and that the BCRP gene is estrogen responsive (Kamalakaran et 
al., 2005). However, the regulation of BCRP by estrogen or its conjugates is not 
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limited to transcriptional level through ERE, but also related to posttranslational 
regulation via several signaling pathways.  
Studies by Krishnamurthy et al. have demonstrated that hypoxia also 
increases the mRNA expression of BCRP in three different human cell lines 
(Krishnamurthy et al., 2004). Further computer algorithm analysis of the 
5’-flanking sequence of human BCRP revealed three putative hypoxia response 
elements (HREs), all located upstream of the transcription start site. Using 
site-directed mutagenesis and electrophoretic mobility shift assays (EMSA), it was 
demonstrated that HIF-1 complex specifically binds to the BCRP promoter 
through the only functional HRE (-116 bp) and promotes the transcription of the 
BCRP gene. This upregulation of the BCRP gene by activated HIF-1 under 
hypoxia condition might be responsible for one of the mechanisms in some 
tumors that facilitate drug resistance. Moreover, IL-6 or ER stress inducer could 
synergistically increase BCRP expression through the site overlapping XBP-1 and 
HIF-1 binding sites on the BCRP promoter, indicating HRE might be involved in 
the effect of ER stress on BCRP expression (Nakamichi et al., 2009).  
Besides ERE and HRE, nuclear receptor responsive elements are usually 
seen in ABC transporter promoters responsible for transcriptional regulation 
(Repa et al., 2000, Chawla et al., 2001). Szatmari et al. first reported upregulation 
of BCRP mRNA in human myeloid lineage, monocyte-derived dendritic cells upon 
PPARγ agonist rosiglitazone treatment (Szatmari et al., 2006). This effect was 
completely abolished by PPARγ antagonist or PPARγ siRNA, indicating that it is 
indeed PPARγ receptor-specific. To elucidate the mechanisms of the above 
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phenomenon, the promoter sequence of the BCRP gene was analyzed, and three 
potential PPAR response elements were found in a conserved region around 150 
bp of length (-3946 to -3796 bp). EMSA analysis further demonstrated that all 
three putative elements were able to bind PPARγ-RXR heterodimers specifically, 
suggesting that this genomic region likely plays an important role in the PPARγ 
dependent transcriptional regulation of BCRP expression. 
Nonetheless, a novel progesterone response element (PRE) has been 
identified between -243 to -115 bp of the BCRP promoter region (Vore and 
Leggas, 2008, Wang et al., 2008). Progesterone significantly increased BCRP 
mRNA level in PGR-B-transfected but not PGR-A-transfected cells. Although 
EMSA confirmed the direct binding of PRE with either PGR-B or PGR-A, 
mutations in PRE only decreased the progesterone-response in 
PGR-B-transfected but not PGR-A-transfected cells, and further deletion of the 
PRE largely abrogated the progesterone effect. Interestingly, cotransfection of 
PGR-A and PGR-B significantly decreased the progesterone-response compared 
with PGR-B transfection alone, indicating progesterone induced BCRP mRNA 
expression through PGR-B, while PGR-A inhibits the effect of PGR-B via an 
undefined mechanism.  
Last but not least, Ebert et al. showed that either AHR or the nuclear factor 
(erythroid-derived 2)-like 2 (Nrf2) agonists could upregulate BCRP mRNA in 
human colon cancer cells (Ebert et al., 2005, 2007). Mechanism studies have 
identified an active, proximal dioxin-response element (DRE) at -194 to -190 bp 
upstream of the transcription start site of the human BCRP gene, which is 
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responsible for the direct binding of AHR and the subsequent induction of BCRP 
mRNA (Tan et al., 2010). Moreover, an antioxidant response element (ARE) at 
-431 to -420 bp of BCRP 5’-UTR is responsible for Nrf2-mediated BCRP 
expression through interaction with Nrf2 (Singh et al., 2010). It is noteworthy that 
the functional DRE is in close proximity to ERE, HRE, as well as PRE, which 
might suggest that the proximal regions of these motifs are essential for the 
recruitment of transcriptional activation machinery onto the BCRP gene and 
promote transcription. However, whether these elements work in concert or 
compete with each other is largely unknown, and further investigation might 
provide valuable information for the characterization of transcriptional regulation 
of BCRP and other ABC transporters.  
3. Posttranscriptional regulation of BCRP 
Human BCRP is extensively N-glycosylated. Sequence analysis revealed 
three potential N-linked glycosylation sites at positions 418, 557 and 596. Through 
site-directed mutagenesis, Asp596 (N596) was demonstrated to be the only 
N-glycosylation site in BCRP (Figure 1). Nonetheless, disruption of 
N-glycosylation modification in BCRP only brought about subtle impairments in 
plasma membrane trafficking and rhodamine 123 transport activity, which 
indicates N-glycosylation on N596 is not essential for the protein expression, 
membrane trafficking, ATPase activities or transport functions (Diop and Hrycyna, 
2005). Mohrmann et al. verified that N596 is the only N-glycosylation site of BCRP 
and that N-glycosylation at 596 is not important for plasma membrane routing 
(Mohrmann et al., 2005).  
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Initially, phosphorylation of BCRP is not detected from the ovarian 
carcinoma cell line T8, and it seems that phosphorylation is not required for BCRP 
functions since substrate transport in T8 cells is effective (Mohrmann et al., 2005). 
However, Xie et al. used a yeast two-hybrid screening assay and identified BCRP 
as one of the interacting partners of Pim-1L, a serine/threonine kinase (Xie et al., 
2008). Pim-1L colocalizes with BCRP on the plasma membrane and induces the 
phosphorylation of BCRP at T362 (Figure 1) in prostate cancer cells. Knocking 
down Pim-1L or T362A mutant resulted in decreased drug resistance, impaired 
plasma membrane localization and reduced BCRP oligomer formation, indicating 
that phosphorylation of BCRP at T362 is crucial for its expression and function.  
BCRP is also under posttranscriptional regulation by microRNAs, a class of 
noncoding RNA genes. In the CD34(+)CD38(-) hematopoietic stem cells isolated 
from human umbilical cord blood, hsa-miR-520h inhibits mRNA expression of 
BCRP and possibly promotes the differentiation of hematopoietic stem cells (Liao 
et al., 2008), while in pancreatic cancer cells, hsa-miR-520h downregulates both 
mRNA and protein levels of BCRP, resulting in inhibition of cell migration and 
invasion (Wang et al., 2010). Interestingly, microRNA binds to a proximal miRNA 
response element (MRE) within the 3’-UTR of BCRP in various cancer cell lines 
and suppresses its expression (Li et al., 2011). However, drug resistant cells lost 
this putative MRE, therefore evading mRNA degradation and protein translation 
repression of BCRP mediated by microRNAs, leading to overexpression of BCRP 
(To et al., 2009). Another microRNA, miR-328, also targets 3’-UTR of the BCRP 
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gene and decreases BCRP mRNA and protein levels through mRNA cleavage 
(Pan et al., 2009). 
4. Epigenetic regulation of BCRP 
Promoter methylation has also been shown to regulate BCRP expression 
in both human multiple myeloma cells and patients’ plasma cells, with 
demethylation of BCRP promoter contributing to increased mRNA and protein 
expression (Turner et al., 2006). The promoter methylation of BCRP was also 
examined in renal carcinoma cell lines. Increased BCRP expression was seen 
after demethylation treatment, indicating that methylation resulted in the silencing 
of the BCRP gene. Chromatin immunoprecipitation assay showed that methylated 
promoter of BCRP interacted with methyl CpG binding domain proteins MBD2 
and MeCP2, which further recruited histone deacetylase 1 and a corepressor, 
resulting in interruption of BCRP transcription (To et al., 2006). Moreover, 
inhibition of DNA methylation in PC-6 lung cancer cells greatly increased both 
mRNA and protein expression of BCRP, and the promoter methylation of BCRP is 
inversely correlated with BCRP expression in both SCLC and NSCLC cells 
(Nakano et al., 2008), indicating that promoter demethylation of BCRP could be a 
common regulatory mechanism for BCRP upregulation in cancer cells. 
In addition, BCRP promoter is also regulated by histone modification. 
Following drug selection in several cancer cell lines, increased histone H3 
acetylation and reduced class I histone deacetylases associated with BCRP 
promoter were observed (To et al., 2008). Increased BCRP expression requires 
three prerequisites, removal of the repressive histone marker (trimethylated 
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histone H3 lysine), recruitment of RNA polymerase II, and recruitment of a 
chromatin-remodeling factor to the BCRP promoter. These studies further 
address the complexity of BCRP gene regulation. 
5. Regulation of BCRP degradation 
Wild-type BCRP is degraded in lysomes. However, misfolded BCRP 
proteins, such as Cys592 and Cys608 mutants, which lack the intramolecular 
disulfide bond and lose proper membrane trafficking, has been shown to be 
removed from the ER by retrotranslocation to the cytosol compartment, 
ubiquitinated by ubiquitin ligase and degraded in proteasomes (Wakabayashi et 
al., 2007, Wakabayashi-Nakao et al., 2009). In addition, Asp596 mutant, which 
lost N-glycosylation important for stabilizing de novo synthesized BCRP, also 
underwent ubiquitin-mediated proteasomal degradation (Nakagawa et al., 2009). 
In a recent study, it has been further revealed that Derlin-1, a part of the complex 
that mediates ER associated degradation (ERAD), promotes the degradation of 
wild-type BCRP through suppression of ER to Golgi transport, therefore providing 
a novel regulatory mechanism of BCRP degradation (Sugiyama et al., 2011).   
6. Pharmacogenetics of BCRP 
Pharmacogenetic variations of human BCRP have brought another level of 
regulation for the expression or function of BCRP, with the most common single 
nucleotide polymorphisms (SNPs) depicted in Figure 1. 
Imai’s group took the first step by isolating BCRP cDNA from 11 cancer cell 
lines for sequencing. Three variants, including G34A (V12M), and C421A 
(Q141K) SNPs and a splicing variant 944-949 deletion (delta315-6) were 
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identified (Imai et al., 2002). In addition, a C376T mutant, which leads to  
premature termination, was present in 3 out of 124 individuals, which resulted in 
loss of expression of BCRP protein (Imai et al., 2002). Zamber et al. moved the 
work forward through a large scale study to investigate the frequencies of all 
known coding region SNPs using DNA samples from 222 human subjects, 
representing eleven distinct ethnic groups (Zamber et al., 2003). Together, nine 
SNPs were identified, including four nonsynonymous, G34A, C421A, A616C 
(I206L), and A1768T (N590Y), as well as three synonymous and two intronic 
SNPs. Of all the SNPs discovered in this study, G34A and C421A are the most 
common.  
G34A and C421A mutants, when expressed in polarized LLC-PK1 cells, 
both displayed significantly increased drug accumulation and decreased drug 
efflux compared to wild-type BCRP. However, the molecular mechanisms of this 
observed drug resistance for G34A and C421A are totally different. Confocal 
microscopy showed that the dysfunction of G34A could be attributed to disturbed 
apical plasma membrane localization, while the dysfunction of C421A mutant is 
due to decreased ATPase activity (Mizuarai et al., 2004, Morisaki et al., 2005). 
The functional analysis of these naturally occurring SNPs might facilitate our 
understanding of the structure-function relationship of BCRP. C421A mutant also 
showed great reduction in protein expression and drug resistance compared to 
wild-type in vitro, although mRNA levels were similar (Imai et al., 2002). However, 
in vivo study failed to identify the difference in intestinal BCRP mRNA or protein 
levels between C421 homozygouts and C421A heterozygouts (Zamber et al., 
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2003), suggesting that other to-be-defined variations in vivo might contribute to 
the expression of BCRP as well.  
G. Modulation of BCRP functions 
In cancer chemotherapy, the ultimate goal targeting BCRP is to inhibit 
BCRP-mediated extrusion of these anticancer drugs to increase the effectiveness 
of treatment. Considerable efforts have been expanded to find chemosensitizers 
that will inhibit the function of BCRP and thereby reverse MDR.  
1. Modulation of BCRP by small molecular inhibitors 
The first inhibitor of BCRP, fumitremorgin C (FTC), was reported before 
BCRP had been discovered and was shown to inhibit resistance in the 
mitoxantrone selected S1-M1-3.2 colon cancer cell line (Rabindran et al., 1998). 
FTC was also shown to specifically inhibit BCRP mediated transport of 
chemotherapeutic agents in stably transfected cell lines (Rabindran et al., 2000). 
Unfortunately, clinical use of FTC was prevented by its neurotoxicity, leading to 
the development of a new tetracyclic analogue of FTC, Ko143 (Allen et al., 2002). 
Ko143 appeared to be a specific and potent inhibitor of both human BCRP and 
murine Bcrp. Most importantly, Ko143 was nontoxic in vitro at therapeutic 
concentrations and in vivo in mice either through oral or intraperitoneal 
administration (Allen et al., 2002). Subsequently, other FTC-type inhibitors, 
including the indolyl diketopiperazines (van Loevezijn et al., 2001) and tryprostatin 
A (Woehlecke et al., 2003) were screened and assessed.   
On the other hand, numerous ABCB1 inhibitors were examined for their 
ability to inhibit BCRP. For example, a potent ABCB1 inhibitor elacridar 
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(GF120918) was also a BCRP inhibitor (de Bruin et al., 1999, Maliepaard et al., 
2001b). Reserpine has also been shown to inhibit BCRP-mediated Hoechst 
33342 transport (Zhou et al., 2001, Wierdl et al., 2003), and cyclosporin A has 
been demonstrated to inhibit ATPase activity of BCRP (Ozvegy et al., 2001, Qadir 
et al., 2005). Other specific ABCB1 inhibitors that have demonstrated potent 
BCPR inhibition include tariquidar (XR9576) (Robey et al., 2004), PSC-833 
(Garcia-Escarp et al., 2004), a series of newly synthesized 1,4-dihydropyridines 
and pyridines, such as dihydropyridines, niguldipine, nicardipine and nitrendipine 
(Zhou et al., 2005b), and chromanone derivatives, such as 
piperazinobenzopyranones and phenalkylaminobenzopyranones (Boumendjel et 
al., 2005).  
Recently, several TKIs have been shown to act as BCRP inhibitors. First, 
CI1033 was shown to reverse BCRP mediated resistance to SN-38 and topotecan 
(Erlichman et al., 2001). Gefitinib (Iressa; ZD1839) has also been shown to inhibit 
BCRP mediated drug resistance, as do imatinib mesylate (Gleevec, STI571), 
EKI-785, nilotinib, erlotinib, lapatinib and sunitinib at low concentrations 
(Houghton et al., 2004, Ozvegy-Laczka et al., 2004, Nakamura et al., 2005, 
Brendel et al., 2007, Shi et al., 2007, Dai et al., 2008, Dai et al., 2009). Since 
BCRP has been shown either to directly transport or to confer resistance to 
CI1033, gefitinib, and imatinib (Burger et al., 2004, Elkind et al., 2005), it is likely 
that these TKIs act as competitive inhibitors. 
Flavonoids, a class of polyphenolic compounds widely present in foods 
and herbal products, are also found to be another class of BCRP inhibitors. 
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Silymarin, hesperetin, quercetin, and daidzein, as well as the stilbene resveratrol, 
were shown to increase intracellular accumulation of mitoxantrone and 
BODIPY-prazosin in BCRP overexpressing cells (Cooray et al., 2004). Similarly, 
chrysin and biochanin A have also been shown to be potent inhibitors of BCRP 
(Zhang et al., 2004b). It has also been reported that genestein, naringenin, 
acacetin, kaempferol and glycosylated flavonoids reversed resistance to SN-38 
and mitoxantrone in BCRP overexpressing K562 cells (Imai et al., 2004). It has 
also been postulated that flavonoids inhibit BCRP via interaction with its NBD 
(Morris and Zhang, 2006). Treatment with multiple flavonoids has revealed an 
additive effect in BCRP inhibition, implying the approach of ‘flavonoid cocktails’ 
might achieve ideal effects in reversing MDR of BCRP (Zhang et al., 2004a).    
Several other potent BCRP inhibitors include novobiocin, an 
aminocoumarin antibiotic that could decrease resistance to topotecan, SN-38 and 
mitoxantrone at low concentrations through competitive inhibition (Shiozawa et al., 
2004). UCN-01, a cyclin-dependent kinase inhibitor, could also inhibit 
BCRP-mediated xenobiotics transport (Robey et al., 2004). Some human 
immunodeficiency virus protease inhibitors (HPIs), including ritonavir, saquinavir, 
nelfinavir, and Iopinavir could effectively inhibit the transport activity of wildtype 
BCRP (482R), with less effect on its mutants (482T/G). None of the HPIs tested 
were BCRP substrates, indicating BCRP expression should be taken into account 
for drug-drug interaction when HPIs are coadministered with BCRP substrates 
(Gupta et al., 2004, Weiss et al., 2007).  
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Moreover, curcumin represents a current trend of screening natural 
compounds for cancer chemotherapy. Curcumin could inhibit the transport and 
resistance of mitoxantrone or PhA in BCRP overexpressing cells, without 
affecting ATP binding or expression of BCRP (Chearwae et al., 2006). 
Tetrahydrocurcumin (THC), a major metabolite of curcumin, also exhibited potent 
inhibition of BCRP, ABCB1 and ABCC1 (Limtrakul et al., 2007). More importantly, 
THC inhibited the binding of IAAP with BCRP, implying that THC inhibits BCRP 
function through direct interaction with the drug binding site of BCRP, instead of 
an off-target effect. 
Our group has also discovered a novel inhibitor of BCRP, PZ-39. It has 
been shown that PZ-39 directly inhibits the transport activity of BCRP acutely and 
accelerates the lysosome degradation pathway of BCRP chronically. It is so far a 
potent and specific BCRP inhibitor, which has no effect on ABCB1 or ABCC1 
(Peng et al., 2009). Inhibitor induced BCRP degradation provides a novel 
mechanism of BCRP inhibition and might become an effective way of reversing 
BCRP-mediated MDR (Peng et al., 2010).  
Recently, the development of broad-spectrum MDR modulators has also 
demonstrated their value in reversing MDR mediated by several ABC transporters. 
The semisynthetic taxane analogue ortataxel inhibits drug efflux mediated by 
ABCB1, ABCC1 and BCRP. However, ortataxel is not optimal as a clinical MDR 
reversing agent because of its cytotoxicity, imposed by the C-13 side chain of the 
taxane molecule, which inhibits microtubule depolymerization. Therefore, 
noncytotoxic taxane-based reversal agents (tRA) were designed by eliminating 
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the C-13 side chain, and the resulting tRA 98006 (Brooks et al., 2003) strongly 
modulates daunorubicin and mitoxantrone efflux and sensitizes the cells 
overexpressing the three MDR transporters to their cytotoxicities. Interestingly, 
another tRA 96023 modulates only ABCB1 and 482R BCRP, but not ABCC1 
(Minderman et al., 2004a). tRAs might be promising to be developed as 
broad-spectrum MDR modulators in the future. In addition, the pipecolinate 
derivative VX-710 (biricodar; Incel) has also shown inhibitory effects toward 
ABCB1, ABCC1 and 482R BCRP (Minderman et al., 2004b), while a novel class 
of tetrahydroisoquinolin-ethyl-phenylamine (WK-X-34 and XR9577) brought 
superior effectiveness in ABCB1 and BCRP inhibition (Jekerle et al., 2006, 
Jekerle et al., 2007), suggesting their potentials as clinical broad-spectrum MDR 
modulators.  
2.    Modulation of BCRP by gene therapy 
Besides direct inhibition of ABC transporter functions, suppression of the 
expression of the BCRP gene through hammerhead ribozyme-based or antisense 
oligonucleotide-based treatment has been demonstrated to be a powerful 
therapeutic strategy to overcome drug resistance mediated by ABC transporters 
(Kobayashi et al., 1994, Stuart et al., 2000). Hammerhead ribozyme destroys 
target genes directly via endoribonucleolytic activities, and it can be designed to 
cleave a specific mRNA molecule with a certain motif, thus might also be applied 
for downregulation of BCRP gene, therefore restoring drug sensitivity of cancer 
cells overexpressing BCRP. Kowalski’s group designed six hammerhead 
ribozymes directed against the BCRP encoding gene. One such anti-BCRP 
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ribozyme, RzB1, showed high endoribonucleolytic cleavage activity at 
physiologicl pH and temperature in a cell free system (Kowalski et al., 2001). After 
being further introduced into cell culture system, RzB1 successfully decreased 
both mRNA and protein levels of BCRP and reversed the drug-resistant 
phenotype, not only in atypical MDR human gastric carcinoma cell lines with 
moderate BCRP expression (Kowalski et al., 2002), but also in MDR MCF7/MX 
cells with a very high expression level of BCRP (Kowalski et al., 2004). Moreover, 
a newly engineered multitarget multiribozyme potently reverses BCRP-mediated 
MDR and inhibits ABCB1 and ABCC2 at the same time (Kowalski et al., 2005). 
This approach provides yet another novel tool for gene therapies against 
broad-spectrum MDR transporters. 
Additionally, antisense oligonucleotide has also been applied to modulate 
BCRP gene expression. Transfer of BCRP antisense oligonucleotide into 
topotecan-resistant ovarian cancer cells brought about a 60% reduction of BCRP 
mRNA and a substantial decrease of resistance index to topotecan, indicating 
antisense oligonucleotide could partially reverse BCRP-mediated drug resistance 
(Jia et al., 2003).   
Recently, a new approach using RNA interference has been applied for the 
specific knockdown of BCRP. siRNA significantly resulted in the downregulation 
of both exogenous and endogenous BCRP, therefore increasing the accumulation 
of topotecan (Ee et al., 2004a). However, Li et al. reported that siRNAs only 
partially reversed the MDR mediated by BCRP, indicating design of 
BCRP-specific siRNA or transfection efficiency might affect the application of this 
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approach in vitro (Li et al., 2005). Nevertheless, Priebsch’s group applied both 
specific anti-BCRP siRNAs and shRNAs in human gastric carcinoma cells with an 
atypical MDR phenotype and achieved complete reversal of MDR mediated by 
BCRP (Priebsch et al., 2006). These data re-assured the feasibility of siRNA- and 
shRNA-mediated gene therapy in reversing BCRP-dependent MDR. 
H. Specific aims of the present work 
BCRP is one of the major ABC transporters involved in the development of 
MDR in cancer chemotherapy. Overexpression of BCRP in tumor cell plasma 
membranes leads to decreased intracellular accumulation of various anticancer 
drugs. BCRP has also been suggested to be important in regulating drug 
bioavailability. Thus, inhibition of BCRP function or expression will increase not 
only the intracellular level of anti-cancer drugs but also the systemic drug levels, 
therefore, reversing multidrug resistance. Compared to other typical ABC 
transporters, BCRP is considered to be a half transporter and it has been shown 
in several studies that the major form of BCRP on the plasma membrane is 
homo-oligomer and its oligomerization domain has been mapped to the domain 
consisting of C-terminal TM5-ECL3-TM6. Furthermore, this oligomerization 
domain hetero-oligomerizes with full-length BCRP and significantly inhibits its 
drug efflux activity. Therefore, the oligomerization of BCRP could be a novel and 
promising target in reversing MDR mediated by BCRP specifically.  
The hypothesis of my project is that TM5, ECL3 or TM6 each plays a role in 
BCRP oligomerization and that this oligomerization formation can be used as a 
target for developing chemosensitizing agents to overcome BCRP-mediated MDR 
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in cancer chemotherapy. To test the above hypotheses, two specific aims are 
accomplished. The first aim is to determine if ECL3 is solely responsible for BCRP 
oligomerization. Using co-immunoprecipitation and chemical cross-linking 
analyses, I have found that ECL3 is essential for the oligomerization of BCRP, 
while neither the three cysteines nor the 569QYFS motif within ECL3 is important 
for the oligomer formation. On the other hand, both TM5 and TM6 contribute to 
oligomer formation, but to a lesser extent when compared to full-length BCRP. 
These data suggest that ECL3, TM5 and TM6 all play a partial role in the 
oligmerization of BCRP and that each domain might contain at least one 
interacting site responsible for the formation of oligomeric BCRP. The second aim 
is to further determine the role of ECL3, TM5 or TM6 in the function of BCRP. Our 
results demonstrated that domain-swapping of TM5/TM6 by TM1/TM2 markedly 
reduced BCRP functions, indicating ECL3 alone is insufficient to retain 
functionality. However, TM5 is a major contributor of BCRP function, while TM6 
alone is not sufficient to retain the transport activity or resistance phenotype of 
BCRP.  
The outcome from this study should lead to a better understanding of how 
TM5, ECL3 and TM6 contribute to the oligomerization and function of BCRP and 
thus extend our knowledge of the structure-function relationship of BCRP and 
help to develop better treatment regimens that may be used to specifically reverse 
the MDR mediated by BCRP. 
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II. Materials and Methods 
A. Materials 
All primers for engineering BCRP constructs with PCR (polymerase chain 
reaction) were obtained from Invitrogen by Life Technologies, Inc. and pfu DNA 
polymerases were purchased from Stratagene by Agilent Techonologies. All DNA 
plasmid preparation kits were from QIAGEN. Cell culture medium DMEM, 
antibiotics, and trypsin were from Cellgro by Mediatech, Inc. and Lonza, 
respectively. DNA and protein molecular weight markers were obtained from 
Fermentas Life Sciences. The chemical cross-linking reagent disuccinimidyl 
suberate (DSS) was from Pierce by Thermo Fisher Scientific. ECL (Enhanced 
chemiluminescence) Western Blot detection reagents were obtained from 
Amersham Pharmacia Biotech by GE Healthcare. All other reagents of analytic 
grade or higher were purchased from Sigma-Aldrich. 
B. Transient and stable cell transfection 
HEK293 cells (human embryonic kidney 293 cells) with stable expression 
of HA-tagged BCRP were grown at 37°C with 5% CO2 in DMEM, supplemented 
with 10% fetal bovine serum, 100 units/ml penicillin, 100 µg/ml streptomycin, with 
the presence of 0.3 mg/ml G418. For transient transfection, pcDNA 3.1(+) plasmid 
containing different Myc-tagged BCRP constructs or vector control were 
transfected into HEK293 cells or HEK293 cells with stable expression of 
HA-tagged BCRP at 90% confluency using LipofectAMINE according to the 
manufacturer's instructions. The cells were harvested for cell lysate preparations 
24 hours after transient transfection. 
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HEK293 cells were grown at 37°C with 5% CO2 in DMEM, supplemented 
with 10% fetal bovine serum, 100 units/ml penicillin, and 100 µg/ml streptomycin. 
For stable transfection, pcDNA 3.1(+) plasmid containing different Myc-tagged 
BCRP constructs or vector control were first transfected into HEK293 cells using 
LipofectAMINE according to the manufacturer's instructions. 48 hours following 
transfection, different dilutions of the transfected cells were selected with 0.8 
mg/ml of G418 for 3 weeks. The stable clones with similar expression levels of all 
Myc-tagged BCRP constructs were verified by Western Blot and maintained in 0.3 
mg/ml G418. 
C. Cell lysate preparation 
For cell lysate preparation, cells were harvested and lysed in ice-cold lysis 
buffer (150 mM NaCl, 25 mM Tris, pH 7.4, 1 mM EDTA, 1% Triton X-100, with 
freshly added 2 mM PMSF and 1 mM DTT before use). The cell lysates were 
passed through 26 gauge needles at least 20 times followed by incubation of 30 
minutes on ice. The lysates were then centrifuged at 12,000 × g for 15 minutes. 
Protein concentrations were determined by Bio-Rad protein assay dye kit, and the 
absorbance was measured by SmartSpec 3000 Spectrophotometer (Bio-Rad 
Laboratories, Inc.). 
D. Co-immunoprecipation and Western Blot 
For co-immunoprecipation, 500 µg fresh cell lysates were mixed with 2 µg 
normal mouse IgG, diluted to 1 ml with ice-cold lysis buffer used for cell lysate 
preparation and incubated for 2 hours at 4°C. The suspensions were precleared 
with 40 µl protein G-PLUS agarose beads (Santa Cruz Biotechnology, Inc.) for 2 
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hours at 4°C. After brief centrifugation at 500 × g for 1 minute, the supernatants 
were transferred to new microcentrifuge tubes and precipitated with monoclonal 
mouse anti-Myc (Cell Signaling Technology, 1:500 dilution) or anti-HA antibodies 
(Covance, 1:500 dilution) for 4 hours at 4°C. After centrifugation at 10,000 × g for 
15 minutes at 4°C, the immune complexes in supernatants were transferred to 
fresh microcentrifuge tubes and were allowed to bind to 40 µl protein G-PLUS 
agarose beads overnight at 4°C with constant rotation. Agarose beads were 
washed 5 times with 1 ml lysis buffer, and the immunoprecipitates were 
resuspended in 40 µl 2× SDS-PAGE sample buffer. 
For Western Blot analysis, cell lysates or immunoprecipitates were 
denatured in 2 × SDS-PAGE sample buffer for 30 minutes at room temperature. 
The samples were subjected to SDS-PAGE on 10% or 12% Tris-glycine 
SDS-polyacrylamide gel. The separated proteins were transferred onto a 
polyvinylidene fluoride membrane (Osmonics, Inc) and blocked in TBST (50 mM 
Tris, 150 mM NaCl, 0.1% Tween 20) containing 5% nonfat milk for 1 hour at room 
temperature. The membranes were then incubated with the primary antibodies for 
1 hour at room temperature. The bound antibodies were detected with 
horseradish peroxidase (HRP)-conjugated Rat anti-mouse Kappa IgG 
(SouthernBiotech) using ECL detection reagents.  
E. Plasma membrane preparation 
Plasma membranes were prepared as described previously with minor 
modifications (Yang et al., 2002).  Briefly, the cells were washed with ice-cold 
PBS and resuspended in hypotonic buffer (10 mM KCl, 1.5 mM MgCl2, 10 
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mM Tris, pH 7.4, 2 mM PMSF) at 106 cells/ml followed by homogenization and 
centrifugation at 1,000 × g for 10 min. The plasma membrane fractions were 
prepared by layering the 1,000 × g supernatant on top of a 35% sucrose cushion 
containing 10 mM Tris, pH 7.4 and 1 mM EDTA, followed by centrifugation at 
38,000 rpm for 1 h. The membranes at the interface between the supernatant and 
the sucrose cushion were collected, mixed with STBS buffer (250 mM sucrose, 
150 mM NaCl and 10 mM Tris, pH 7.5) and pelleted by centrifugation at 29,000 
rpm for 1 h. The final membrane pellets were resuspended in STBS buffer and 
stored at -80°C.  
F. Chemical cross-linking 
Chemical cross-linking was performed with DSS. Briefly, confluent cells in 
150 mm dishes were washed three times with KCl/Hepes buffer (90 mM KCl, 50 
mM Hepes, pH 7.5) and incubated with 2 mM DSS in the KCl/Hepes buffer for 45 
minutes at room temperature. Tris-HCl (pH 7.4) was added to a final 
concentration of 2 mM to quench the reaction. The cells were then collected for 
plasma membrane preparation as described above. 5 µg of plasma membranes 
treated with DSS dissolved in DMSO or DMSO only were treated with an equal 
volume of 2 × SDS extraction buffer for 30 minutes at room temperature followed 
by centrifugation at 11,000 × g for 10 minutes. The supernatants were then 
loaded onto precast 4-15% gradient Tris/glycine polyacrylamide gels (Bio-Rad 
Laboratories, Inc.), and electrophoresis was run at 140 volts with SDS running 
buffer. Proteins were transferred to polyvinylidene fluoride membranes followed 
by detection with Western Blot.  
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G. MTT assay 
A total of 3,000 HEK293 stable cells were plated in 96-well flat bottom 
plates for 24 hours and then exposed to Adriamycin (0, 1.6, 6.4, 25.6, 102.4, 410, 
1640 ng/mL), or mitoxantrone (0, 4, 16, 64, 256, 1024, 4096 nM). After 72 hours, 
20 µL of 5 mg/mL MTT solution in PBS were added to each well. After brief 
centrifugation and removal of the medium, 100 µl of DMSO was added to each 
well to dissolve the formazan crystals. The absorbance at 540 nm was 
determined using a MRX absorbance reader (Dynex Technologies, Inc.). 
Triplicate wells were assayed for each condition, and S.D. was determined.  
H. Drug accumulation assay 
The drug accumulation assay was performed as previously described 
(Peng et al., 2009) with minor modifications. 106 cells were trypsinized, 
resuspended in 1 mL DMEM with 20 µM mitoxantrone, and incubated at 37°C for 
30 minutes. Cells were then collected by centrifugation at 500 × g and washed 
three times with ice-cold DMEM. The cells were then resuspended in 1 mL DMEM 
and subjected to analysis by flow cytometry using BD FACSCalibur APC Analyzer. 
The data were analyzed using Cell Quest Pro (BD Biosciences). 
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III. Experimental Results 
A. ECL3 is responsible for oligomerization in truncated BCRP construct 
In a previous study, it has been demonstrated that the oligomerization site 
of BCRP is located in its C-terminus consisting of TM5-ECL3-TM6 (Xu et al., 
2007). To further map the oligomerization site, we dissected this region into three 
domains containing TM5, ECL3 and TM6, respectively. Through sequence 
alignment, we have found that ECL3 is highly conserved among human, rat and 
mouse (Figure 3). Moreover, Cys603, Cys592 and Cys608, which are responsible 
for the formation of intermolecular and intramolecular disulfide bond in BCRP 
(Wakabayashi et al., 2007), are located in ECL3. A QXXS motif (569QYFS), which 
has been shown to facilitate the transmembrane domain interactions in 
membrane proteins (Sal-Man et al., 2005), was also found in the ECL3 of BCRP 
and is conserved among human, rat and mouse (Figure 3). Therefore, I first 
tested if ECL3 is responsible for BCRP oligomerization. Since it was previously 
found that ectopically expressed Myc-BCRPTM12 construct consisting of the 
N-terminal NBD through TM2 (Figure 4A-2) retained plasma membrane trafficking 
yet did not confer oligomerization activity, I engineered a construct by swapping 
the ECL1 in Myc-BCRPTM12 to ECL3, resulting in the Myc-tagged construct of 
Myc-BCRPTM12–ECL3 (Figure 4A-3), to investigate the sole role of ECL3 in the 
oligomerization of BCRP. This construct, together with Myc-BCRPTM56 (Figure 
4A-1) as a positive control and Myc-BCRPTM12 as a negative control (Xu et al., 
2007), was transiently transfected into HEK293 stable cells that stably expressing 
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HA-tagged full-length BCRP (Figure 4, HA-BCRPFLWT), to determine if Myc- 
BCRPTM12–ECL3 interacts with the full-length BCRP. 
Twenty-four hours after transfection, cell lysates were collected and tested 
for co-expression of the full-length and truncated BCRP constructs via Western 
Blot using either anti-HA or anti-Myc antibodies. All constructs were well 
expressed in HEK293 stable cells (Figure 4B). These lysates were then subjected 
to co-immunoprecipitation using anti-Myc antibodies (Figure 4C) followed by 
Western Blot analyses probed with anti-HA antibodies. As shown in Figure 4C, 
Myc-BCRPTM12–ECL3 co-immunoprecipitates HA-BCRPFLWT (lane 3). A detailed 
analysis of the amount of coprecipitated BCRP constructs after normalization to 
their expression levels shows that the relative level of coprecipitation of 
Myc-BCRPTM12–ECL3 is reduced compared to Myc-BCRPTM56 (Figure 4D). 
Therefore, the replacement of ECL1 by ECL3 (Myc-BCRPTM12–ECL3) enabled its 
interaction with HA-BCRPFLWT, to a lesser extent when compared to 
Myc-BCRPTM56, suggesting that ECL3 alone plays a partial role in the 
oligomerziation of BCRP. 
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Figure 3: Sequence alignment of human BCRP, rat, and mouse Bcrp1. The 
sequence alignment shows over 90% similarity between rat and mouse Bcrp1 
ECL3, and around 80% similarity between human BCRP ECL3 and rat/mouse 
Bcrp1 ECL3. The conserved 569QYFS motif is indicated in underlined red letter, 
while the three cysteines in ECL3 are indicated in underlined blue letter. The 
multiple sequence alignment is performed by ClustalW2 software 
(http://www.ebi.ac.uk/Tools/services/web/toolform.ebi?tool=clustalw2). 
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Figure 4: ECL3 is responsible for BCRP oligomerization in truncated BCRP 
construct. (A) Schematic diagram of HA-BCRPFLWT and the truncated 
Myc-BCRPTM56 (1), truncated Myc-BCRPTM12 (2), and the domain-swapping 
Myc-BCRPTM12-ECL3 (3) constructs. The TM segments are numbered and shown as 
boxes. The HA-tag and the Myc tag are shown as a circle and oval, respectively. 
NBD, ECL1 and ECL3 are also indicated. (B) Expression of the above BCRP 
constructs after transfection. (C) co-immunoprecipitation analysis of the above 
BCRP constructs. The Myc-tagged constructs were transiently transfected into 
HEK293 cells with stable expression of HA-BCRPFLWT. Cell lysates were collected 
24 hours after transient transfection and 400 µg total proteins was subjected to 
co-immunoprecipitation with anti-Myc antibodies followed by Western Blot 
analysis (IB). (D) Quantification of co-immunoprecipitation. The 
co-immunoprecipitation levels of constructs in (C) were quantified using 
ScnImage followed by calculation of the relative ratio of co-immunoprecipitation to 
expression level (B), N=3. 
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B. ECL3 is responsible for oligomerization in full-length BCRP 
To further confirm ECL3 is an essential component of the oligomerization 
domain and to minimize the effect of domain truncation on the expression or 
function of BCRP, I engineered a second domain-swapping construct, 
Myc-BCRPFL-ECL3 (Figure 5A-3), based on full-length BCRP. I have chosen TM1 
and TM2 to replace TM5 and TM6 respectively, since TM1 and TM2 have been 
demonstrated to retain no oligomerization activity both in previous studies (Xu et 
al., 2007) and my studies (Figure 4C). Meanwhile, Myc-BCRPFL-TM14 (Figure 5A-1), 
which has also been confirmed to abolish oligomerization activity (Xu et al., 2007), 
was used as a negative control. These two constructs, together with 
Myc-BCRPFLWT (Figure 5A-2) as a positive control, were transiently transfected 
into HEK293 cells with stable expression of HA-BCRPFLWT, respectively. All these 
contructs are well expressed as detected by Western Blot (Figure 5B). We next 
performed co-immunoprecipitation experiments with anti-HA antibodies (Figure 
5C) followed by Western Blot analysis of the precipitates. As shown in Figure 5C, 
Myc-BCRPFL-ECL3 co-precipitateS with HA-BCRPFLWT (Figure 5C, lane 3), whereas 
Myc-BCRPFL-TM14 did not (Figure 5C, lane 1), suggesting that ECL3 in full-length 
BCRP is responsible for the oligomerization of BCRP. Similar results were 
observed for co-immunoprecipitation with anti-Myc antibodies and Western Blot 
probed with anti-HA antibodies (Figure 5E). Quantification of the coprecipitated 
BCRP constructs after normalization to their expression levels shows that the 
relative level of coprecipitation of Myc-BCRPFL-ECL3 is decreased compared to 
Myc-BCRPFLWT (Figure 5D and 5F), which is consistent with the previous results 
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of Myc-BCRPTM12–EC3 (Figure 4), confirming that ECL3 plays a partial role in 
BCRP oligomerization.  
C. The cysteines in ECL3 are not essential for BCRP oligomerization 
It has been shown that ECL3 of BCRP contains three cysteines, Cys603, 
Cys592 and Cys608, which are responsible for the formation of inter- and 
intra-molecular disulfide bonds (Wakabayashi et al., 2006). It has also been 
postulated that the disulfide bonds are possibly involved in the formation of BCRP 
dimer/oligomer (Kage et al., 2005). In order to investigate if these three cysteines 
are essential for BCRP oligomerization mediated by ECL3, I engineered a 
Myc-BCRPFL-ECL3-3CL construct (Figure 5A-4) with all three cysteines mutated to 
alanines. This construct was transiently transfected into HEK293 cells stably 
expressing HA-BCRPFLWT and its expression was confirmed by Western Blot 
(Figure 5B, lane 4). Figure 5 demonstrates that following co-immunoprecipitation 
with anti-HA antibodies (Figure 5C, lane 4) and Western Blot analysis probed with 
anti-Myc antibodies, Myc-BCRPFL-ECL3-3CL co-precipitates with HA-BCRPFLWT of a 
comparable level as Myc-BCRPFL-ECL3 after normalization to protein expression 
levels (Figure 5D), indicating that these three cysteines or the disulfide bonds 
formed by them are not essential in BCRP oligomerization. 
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Figure 5: (Legend on next page).  
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Figure 5: The ECL3 is responsible for oligomerization in full-length BCRP 
and cysteines or the 569QYFS motif in ECL3 is not essential for BCRP 
oligomerization. (A) Schematic diagram of HA-BCRPFLWT, truncated 
Myc-BCRPTM14 (1), Myc-BCRPFLWT (2) and the domain-swapping constructs 
Myc-BCRPFL-ECL3 (3), Myc-BCRPFL-ECL3-3CL (4), Myc-BCRPFL-ECL3-3CL-AYFA (5). The 
TM segments are numbered and shown as boxes. The HA-tag and the Myc tag 
are shown as a circle and oval, respectively. NBD, ECL1 and ECL3 are also 
indicated. (B) Expression of the above BCRP constructs after transfection. (C) 
Co-immunoprecipitation of the above BCRP constructs. The Myc-tagged 
constructs were transiently transfected into HEK293 cells with stable expression 
of HA-BCRPFLWT. 24 hours following transfection, cell lysates were collected and 
400 µg total proteins was subjected to co-immunoprecipitation with HA (C) 
antibodies followed by Western Blot analysis. (D) Quantification of 
co-immunoprecipitation. The co-immunoprecipitation levels of constructs with 
anti-HA antibodies in (C) were quantified using ScnImage followed by calculation 
of the relative ratio of co-immunoprecipitation to expression level. (E) 
Co-immunoprecipitation of the above BCRP constructs with anti-Myc antibodies. 
(F) Quantification results of co-immunoprecipitation with anti-Myc antibodies and 
N=3. 
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Moreover, co-immunoprecipitation analysis with anti-Myc antibodies and 
Western Blot probed with anti-HA antibodies further confirmed the above findings 
(Figure 5E, lane 4). 
D. The 569QYFS motif is not essential for BCRP oligomerization 
We next studied the involvement of the 569QYFS motif (Sal-Man et al., 
2005) in BCRP oligomerization mediated by ECL3. For this purpose, 
Myc-BCRPFL-ECL3-3CL-AYFA construct (Figure 5A-5) was engineered, with the two 
essential polar amino acids (Q and S) in 569QYFS motif mutated to nonpolar 
alanines. This Myc-BCRPFL-ECL3-3CL-AYFA was transfected into HEK293 cells with 
stable expression of HA-BCRPFLWT. As shown in Figure 5, 
Myc-BCRPFL-ECL3-3CL-AYFA is similarly expressed (Figure 5B, lane 5) and 
coprecipitated by HA-BCRPFLWT (Figure 5C, lane 5) as Myc-BCRPFL-ECL3 after 
normalization to protein expression levels (Figure5D). This result was also verified 
by co-immunoprecipitation analysis with anti-Myc antibodies and Western Blot 
with anti-HA antibodies (Figure 5E, lane 5) and quantification analyses (Figure 
5F). All these findings demonstrated that the 569QYFS motif is also not involved in 
BCRP oligomerization.  
E. TM5 and TM6 are essential for the oligomerization of BCRP 
To further investigate the hypothesis that ECL3 is the sole responsible 
element for the oligomerization of BCRP, I designed a domain-swapping 
construct by replacing ECL3 in the Myc-BCRPFLWT with ECL1. This new 
Myc-BCRPFL-TM5TM6 construct (Figure 6A-1), was transiently transfected into 
HEK293 cells with stable expression of HA-BCRPFLWT. All constructs were well 
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expressed as determined via Western Blot using anti-Myc antibodies (Figure 6B). 
Co-immunoprecipitation experiments with either anti-HA antibodies (Figure 6C) or 
anti-Myc antibodies (Figure 6E) were performed followed by Western Blot 
analysis of the precipitate. To our surprise, we found that Myc-BCRPFL-TM5TM6 
(Figure 6C and 6E, lane 1) could also co-precipitate with HA-BCRPFLWT, with a 
slightly lower level as compared with Myc-BCRPFLWT (Figure 6C and 6E, lane 2), 
suggesting that the combination of two flanking transmembrane segments of 
ECL3 is also essential for BCRP to oligomerize.  
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Figure 6: TM5 and TM6 are also essential for BCRP oligomerization. (A) 
Schematic diagram of the domain-swapping Myc-BCRPFL-TM5TM6 construct (1), 
Myc-BCRPFLWT (2) and Myc-BCRPTM14 (3). The TM segments are numbered and 
shown as boxes. The HA-tag and the Myc tag are shown as a circle and oval, 
respectively. These constructs were transiently transfected into HEK293 cells 
stably expressing HA-BCRPFLWT. 24 hours following transfection, cell lysates 
were collected and expression were tested (B). 400 μg total protein was used for 
co-immunoprecipitation with anti-HA (C) and anti-Myc antibodies (E) followed by 
Western Blot analysis probed using the same two antibodies. The 
co-immunoprecipitation levels of constructs were quantified using ScnImage 
followed by calculation of the relative ratio of co-immunoprecipitation to 
expression level. (D) Quantification results of co-immunoprecipitation with anti-HA 
antibodies and N=3. (E) Quantification results of co-immunoprecipitation with 
anti-Myc antibodies. 
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F. Either TM5 or TM6 plays a partial role in BCRP oligomerization  
As shown above, Myc-BCRPFL-TM5TM6 is sufficient to interact with the 
full-length BCRP. It is of interest to determine if either TM5 or TM6 is essential for 
BCRP oligomerization. For this purpose, two additional domain-swapping 
constructs, Myc-BCRPFL-TM5 (Figure 7A-1), with ECL3 and TM6 replaced by ECL1 
and TM2, and Myc-BCRPFL-TM6 (Figure 7A-2), with TM5 and ECL3 replaced by 
TM1 and ECL1, were engineered to investigate the responsibility of TM5 or TM6 
in BCRP oligomerization. These two constructs were transiently transfected into 
HEK293 cells stably expressing HA-BCRPFLWT, respectively. All constructs were 
well expressed as determined via Western Blot using Myc antibodies (Figure 7B). 
I next performed co-immunoprecipitation using the anti-HA antibodies (Figure 7C) 
or Myc antibodies (Figure 7E) followed by Western Blot analysis probed by HA or 
Myc antibodies. It is clearly shown that either Myc-BCRPFL-TM5 (Figure 7C and 7E, 
Lane 1) or Myc-BCRPFL-TM6 (Figure 7C and 7E, Lane 2) could co-precipitate with 
HA-BCRPFLWT, suggesting that either TM5 or TM6 alone can interact with 
full-length BCRP. However, compared to Myc-BCRPFLWT (Figure 7C and 7E, Lane 
3), both Myc-BCRPFL-TM5 and Myc-BCRPFL-TM6, showed a decreased ability to 
interact with HA-BCRPFLWT after normalization to protein expression level (Figure 
7D for co-immunoprecipitation with anti-HA antibodies and 7F for 
co-immunoprecipitation with anti-Myc antibodies), indicating that TM5 and TM6 
each has only partial contribution in BCRP oligomerization.   
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Figure 7: Either TM5 or TM6 in full-length BCRP is partially responsible for 
oligomerization. (A) Schematic diagram of HA-BCRPFLWT and Myc-BCRPFL-TM5 
(1), Myc-BCRPFL-TM6 (2), Myc-BCRPFLWT (3), Myc-BCRPTM14 (4) constructs. The 
HA-tag and the Myc tag are shown as a circle and oval, respectively. NBC, ECL1 
and ECL3 are also indicated. These constructs were transiently transfected into 
HEK293 cells stably expressing HA-BCRPFLWT. 24 hours following transfection, 
cell lysates were collected and expression were tested (B). 400 μg total protein 
was used for co-immunoprecipitation with HA (C) and anti-Myc antibodies (E) 
followed by Western Blot analysis probed using the same two antibodies. The 
co-immunoprecipitation levels of constructs were quantified using ScnImage 
followed by calculation of the relative ratio of co-immunoprecipitation to 
expression level. (D) Quantification results of co-immunoprecipitation with anti-HA 
antibodies. (E) Quantification results of co-immunoprecipitation with anti-Myc 
antibodies and N=3. 
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G. Chemical cross-linking analyses of domain-swapping BCRP 
constructs in living cells 
We next determined if BCRP domain-swapping constructs 
Myc-BCRPFL-ECL3, Myc-BCRPFL-ECL3-3CL, Myc-BCRPFL-ECL3-3CL-AYFA, 
Myc-BCRPFL-TM5 or Myc-BCRPFL-TM6 could form oligomers by themselves in living 
cells. For this purpose, chemical cross-linking experiments of living cells using 
disuccinimidyl suberate (DSS) were conducted as previously described (Xu et al., 
2004). HEK293 cells stably expressing Myc-BCRPFLWT, domain-swapping 
Myc-BCRPFL-ECL3, Myc-BCRPFL-ECL3-3CL, Myc-BCRPFL-ECL3-3CL-AYFA, 
Myc-BCRPFL-TM5 or and Myc-BCRPFL-TM6 were established and used for the 
cross-linking assay.  
Following 2 mM DSS treatment, plasma membranes were isolated and 
subjected to SDS-PAGE and Western Blot analyses with anti-Myc antibodies. As 
shown in Figure 8A, three bands of Myc-BCRPFLWT with molecular weight greater 
than that of the monomeric BCRP were detected following corss-linking by DSS, 
as compared with the control without DSS. The estimated sizes of these bands 
are close to 292, 219, 146 and 73 kD, corresponding to the sizes of tetrameric, 
trimeric, dimeric and monomeric Myc-BCRPFLWT. This is consistent with the 
previously reported results (Xu et al., 2004).  
On the other hand, Myc-BCRPFL-ECL3 (Figure 8B, right panel), 
Myc-BCRPFL-ECL3-3CL (Figure 8B, middle panel) and Myc-BCRPFL-ECL3-3CL-AYFA 
(Figure 8B, left panel) stable cells showed identical cross-linking products profiles 
with two major cross-linked products. The estimated molecular weights of these 
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products are close to 292, 146kD, corresponding to the size of tetrameric and 
dimeric Myc-BCRPFL-ECL3-3CL-AYFA, Myc-BCRPFL-ECL3-3CL, or Myc-BCRPFL-ECL3. The 
chemical cross-linking results confirmed that ECL3 alone plays a partial role in the 
oligomerization of BCRP and that neither three cysteines in the ECL3 nor the 
569QYFS motif is necessary for the oligomerization of BCRP. 
In addition, chemical cross-linking analyses with DSS were also performed 
in living Myc-BCRPFL-TM5 and Myc-BCRPFL-TM6 stable cells to further determine if 
Myc-BCRPFL-TM5 or Myc-BCRPFL-TM6 each forms oligomers in living cells. As 
shown in Figure 8, Myc-BCRPFL-TM5 (Figure 8C) and Myc-BCRPFL-TM6 (Figure 8D) 
expressed on the plasma membrane have two major cross-linked products. The 
estimated molecular weights of these products are close to 264 and 132kD, 
corresponding the sizes of tetrameric and dimeric Myc-BCRPFL-TM5 or 
Myc-BCRPFL-TM6. The non-crosslinked monomeric Myc-BCRPFL-TM5 or 
Myc-BCRPFL-TM6 has an apparent molecular weight of ~64 kD on SDS-PAGE. 
These results clearly suggest that either TM5 or TM6 is partially responsible for 
the oligomerization of BCRP.  
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Figure 8: Chemical cross-linking analyses of BCRP domain-swapping 
constructs.10 µg of plasma membranes isolated from the stably transfected 
HEK293 cells with Myc-BCRPFLWT, domain-swapping Myc-BCRPFL-ECL3, 
Myc-BCRPFL-ECL3-3CL, Myc-BCRPFL-ECL3-3CL-AYFA, Myc-BCRPFL-TM5 or 
Myc-BCRPFL-TM6, and truncated Myc-BCRPTM14 treated with or without 2mM DSS 
were separated by SDS-PAGE followed by Western Blot analysis. The sizes of all 
the constructs were estimated based on linear regression of the protein markers 
used.  
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H. ECL3 is insufficient for BCRP transport activity or drug resistance 
mediated by BCRP 
As shown above, Myc-BCRPFL-ECL3 plays a partial role in the 
oligomerization of BCRP. Next, I proceeded to investigate the functional 
significance of ECL3. For this purpose, I tested and compared the drug resistance 
cytotoxicity of HEK293 cells stably expressing vector control, Myc-BCRPFLWT, 
Myc-BCRPFL-ECL3 and Myc-BCRPFL-TM5TM6 to either mitoxantrone or Adriamycin. 
As shown in Figure 9-10, the cells expressing Myc-BCRPFLWT alone are resistant 
to both mitoxantrone (Figure 9A) and Adriamycin (Figure 10A) compared with 
cells transfected with vector alone. However, compared with Myc-BCRPFLWT 
stable cells, Myc-BCRPFL-ECL3 stable cells have significantly reduced mitoxantrone 
(Figure 9B) and Adriamycin (Figure 10B) resistance with a decrease in RRF 
(relative resistance factor) by 50% after normalization to the average plasma 
membrane expressions. On the other hand, Myc-BCRPFL-TM5TM6 stable cells, 
without ECL3, have shown similar mitoxantrone (Figure 9B) and Adriamycin 
(Figure 10B) resistance as the wildtype BCRP after normalization to the 
expression levels of these constructs on the plasma membranes, indicating TM5 
and TM6 are responsible for BCRP functions. Figure 11 shows the plasma 
membrane expression level of the above BCRP constructs as determined by 
Western Blot analyses with anti-Myc antibodies.  
To further confirm the results from drug resistance cytotoxicity assays, 
drug accumulation activity of HEK293 cells stably expressing vector control, 
Myc-BCRPFLWT, Myc-BCRPFL-ECL3 and Myc-BCRPFL-TM5TM6 were tested. Figure 12 
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(A) shows typical profiles of mitoxantrone accumulation in these cells as 
determined by FACS. The relative accumulation of mitoxantrone reduced 
markedly in both Myc-BCRPFLWT and Myc-BCRPFL-TM5TM6 stable cells, while 
Myc-BCRPFL-ECL3 expressing cells showed similar drug accumulation as vector 
expressing cells (Figure 12B), suggesting that ECL3 alone is insufficient to retain 
the drug efflux activity of BCRP and drug resistance mediated by BCRP. 
Furthermore, disrupting the oligomerization activity mediated by ECL3 alone 
(shown by results of Myc-BCRPFL-TM5TM6) do not affect BCRP activity, indicating 
the inter-domain interactions between ECL3s, which is partially responsible for 
the formation of BCRP oligomers, is not necessary for BCRP transport activities 
or drug resistance mediated by BCRP.  
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Figure 9: Effect of ECL3 on mitoxantrone resistance. Vector-transfected, 
Myc-BCRPFLWT, Myc-BCRPFL-ECL3 and Myc-BCRPFL-TM5TM6 stable cells were 
treated with various concentrations of mitoxantrone followed by analysis using 
MTT assy. Dose-survival curves (A) were fitted using Prism software (version 
3.02). Relative resistance factor (RRF) (B) was derived by normalizing the IC50 of 
Myc-BCRPFLWT, Myc-BCRPFL-ECL3 or Myc-BCRPFL-TM5TM6 to the IC50 of the 
vector transfected stable cells and further to the average plasma membrane 
expression of the above constructs. # p<0.01. 
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Figure 10: Effect of ECL3 on Adriamycin resistance. Vector-transfected, 
Myc-BCRPFLWT, Myc-BCRPFL-ECL3 and Myc-BCRPFL-TM5TM6 stable cells were 
treated with various concentrations of Adriamycin followed by analysis using MTT 
assy. Dose-survival curves (A) were fitted using Prism software (version 3.02). 
Relative resistance factor (RRF) (B) was derived by normalizing the IC50 of 
Myc-BCRPFLWT, Myc-BCRPFL-ECL3 or Myc-BCRPFL-TM5TM6 to the IC50 of the 
vector transfected stable cells and further to the average plasma membrane 
expression of the above constructs. # p<0.01. 
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Figure 11: Expression levels of BCRP constructs in the plasma membrane 
vesicles extracted from HEK293 stable cell clones. (A) 5µg plasma 
membrane extracted from HEK293 cells stably expression Myc-BCRPFLWT (1), 
Myc-BCRPFL-TM5 (2), Myc-BCRPFL-TM6 (3), Myc-BCRPFL-ECL3 (4), 
Myc-BCRPFL-TM5TM6 (5), Myc-BCRPFL-TM5ECL3 (6), and Myc-BCRPFL-ECL3TM6 (7) were 
probed with anti-Myc and anti-E-cadherin antibodies as internal control to 
determine the expression of these constructs on the plasma membranes. (B) The 
relative protein expression level was normalized to BCRPFLWT.  
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Figure 12: Effect of ECL3 on mitoxantrone accumulation acitvity. (A) 
Vector-transfected, Myc-BCRPFLWT, Myc-BCRPFL-ECL3 and Myc-BCRPFL-TM5TM6 
stable cells were subject to FACS analysis of mitoxantrone efflux for transport 
activity of BCRP. (B) Relative motixantrone accumulations were normalized to 
vector expressing cells. # p<0.01. 
 
  
 77 
I. TM5 is a major contributor for the drug transport and drug resistance 
mediated by BCRP 
Next, we investigated the contribution of TM5 to drug resistance mediated 
by BCRP. MTT assays with either mitoxantrone or Adriamycin were performed 
with Myc-BCRPFL-TM5, Myc-BCRPFL-ECL3TM6 (TM5 replaced by TM1) (Figure 13A) 
stable cells. As shown in Figure 13-14, compared with Myc-BCRPFLWT stable cells, 
Myc-BCRPFL-TM5 stable cells have a trend of increased mitoxantrone (Figure 13B) 
and Adriamycin (Figure 14B) resistance. In contrast, Myc-BCRPFL-ECL3TM6 stable 
cells, which abolished the activity conferred by TM5, showed a significantly 
decreased mitoxantrone (Figure 13B) and Adriamycin (Figure 14B) resistance 
with a reduction in RRF (relative resistance factor) by more than 50%, indicating 
that TM5 alone is sufficient and necessary for BCRP functions.  
Drug accumulation assays with FACS were also performed in HEK293 
cells stably expressing vector control, Myc-BCRPFLWT, Myc-BCRPFL-TM5, and 
Myc-BCRPFL-ECL3TM6 cells to confirm the above findings. Figure 15A shows typical 
profiles of mitoxantrone accumulation in these cells as determined by FACS. The 
relative accumulation of mitoxantrone is reduced significantly in both 
Myc-BCRPFLWT and Myc-BCRPFL-TM5 stable cells, while Myc-BCRPFL-ECL3TM6 
expressing cells showed similar drug accumulation as vector expressing cells 
(Figure 15B). These results strongly suggest that TM5 is a major contributor for 
BCRP functions.   
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Figure 13: Effect of TM5 on mitoxantrone resistance. Vector-transfected, 
Myc-BCRPFLWT, Myc-BCRPFL-TM5 and Myc-BCRPFL-ECL3TM6 stable cells (A) were 
treated with various concentrations of mitoxantrone followed by analysis using 
MTT assy. Dose-survival curves (C) were fitted using Prism software (version 
3.02). Relative resistance factor (RRF) (A) was derived by normalizing the IC50 of 
Myc-BCRPFLWT, Myc-BCRPFL-TM5 or Myc-BCRPFL-ECL3TM6 to the IC50 of the 
vector transfected stable cells and further to the average plasma membrane 
expression of the above constructs. # p<0.01. 
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Figure 14: Effect of TM5 on Adriamycin resistance. Vector-transfected, 
Myc-BCRPFLWT, Myc-BCRPFL-TM5 and Myc-BCRPFL-ECL3TM6 stable cells were 
treated with various concentrations of Adriamycin followed by analysis using MTT 
assy. Dose-survival curves (A) were fitted using Prism software (version 3.02). 
Relative resistance factor (RRF) (B) was derived by normalizing the IC50 of 
Myc-BCRPFLWT, Myc-BCRPFL-TM5 or Myc-BCRPFL-ECL3TM6 to the IC50 of the 
vector transfected stable cells and further to the average plasma membrane 
expression of the above constructs. # p<0.01. 
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Figure 15: Effect of TM5 on mitoxantrone accumulation acitvity. (A) 
Myc-BCRPFLWT, Myc-BCRPFL-TM5, Myc-BCRPFL-ECL3TM6 stable cells were subject 
to FACS analysis of mitoxantrone efflux for transport activity of BCRP. (B) 
Relative mitoxantrone accumulations were normalized to vector expressing cells. 
# p<0.01. 
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J. TM6 is insufficient for the drug transport and drug resistance 
mediated by BCRP 
It has been demonstrated that TM6 plays a partial role in the 
oligomerization of BCRP. Here, the effects of TM6 on BCRP functions were 
investigated. Figure 15 and 16 show that Myc-BCRPFL-TM6 stable cells have 
significantly decreased mitoxantrone (Figure 16B) and Adriamycin (Figure 17B) 
resistance with RRF reduced by over 50% compared to Myc-BCRPFLWT stable 
cells (Figure 16C and 17C). On the other hand, Myc-BCRPFL-TM5ECL3 (TM6 
replaced by TM2) (Figure 16A) stable cells, which abolishes the contribution of 
TM6, shows a slightly increased or similar resistance to mitoxantrone (Figure 16B) 
and Adriamycin (Figure 17B), suggesting that TM6 alone is insufficient for the 
functions of BCRP.  
Drug accumulation activity of HEK293 cells stably expressing vector 
control, Myc-BCRPFLWT, Myc-BCRPFL-TM6 and Myc-BCRPFL-TM5ECL3 were also 
tested. Figure 18A shows typical profiles of mitoxantrone accumulation in these 
cells as determined by FACS. The relative accumulation of mitoxantrone was not 
reduced in either Myc-BCRPFL-TM6 stable cells compared to vector-transfected 
cells (Figure 18B), further confirming that TM6 alone is not sufficient for BCRP 
functions. Interestingly, Myc-BCRPFL-TM5ECL3 stable cells also showed similar 
mitoxantrone accumulation as vector-transfected cells.  
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Figure 16: Effect of TM6 on mitoxantrone resistance. Vector-transfected, 
Myc-BCRPFLWT, Myc-BCRPFL-TM6 and Myc-BCRPFL-TM5ECL3 (A) stable cells were 
treated with various concentrations of mitoxantrone followed by analysis using 
MTT assy. Dose-survival curves (B) were fitted using Prism software (version 
3.02). Relative resistance factor (RRF) (C) was derived by normalizing the IC50 of 
Myc-BCRPFLWT, Myc-BCRPFL-TM6 or Myc-BCRPFL-TM5ECL3 to the IC50 of the 
vector transfected stable cells and further to the average plasma membrane 
expression of the above constructs. # p<0.01. 
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Figure 17: Effect of TM6 on Adriamycin resistance. Vector-transfected, 
Myc-BCRPFLWT, Myc-BCRPFL-TM6 and Myc-BCRPFL-TM5ECL3 stable cells were 
treated with various concentrations of Adriamycin followed by analysis using MTT 
assy. Dose-survival curves (A) were fitted using Prism software (version 3.02). 
Relative resistance factor (RRF) (B) was derived by normalizing the IC50 of 
Myc-BCRPFLWT, Myc-BCRPFL-TM6 or Myc-BCRPFL-TM5ECL3 to the IC50 of the 
vector transfected stable cells and further to the average plasma membrane 
expression of the above constructs. # p<0.01. 
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Figure 18: Effect of TM6 on mitoxantrone accumulation acitvity. (A) 
Myc-BCRPFLWT, Myc-BCRPFL-TM6, Myc-BCRPFL-TM5ECL3 stable cells were subject 
to FACS analysis of mitoxantrone efflux for transport activity of BCRP. (B) 
Relative motixantrone accumulations were normalized to vector expressing cells. 
# p<0.01. 
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IV. Discussion 
Human BCRP is considered as a half transporter and exists on the plasma 
membrane as a homo-oligomer. Although there is no consistent conclusion 
concerning the composition of oligomeric BCRP complex, the region that is solely 
responsible for the oligomerization of BCRP has been mapped to C-terminal 
TM5-ECL3-TM6. In addition, introduction of the peptide containing 
TM5-ECL3-TM6 resulted in a marked inhibition of the drug transport activities and 
drug resistance phenotype of BCRP, indicating that the oligomerization of BCRP 
might be functionally significant. Therefore, it is worthwhile to further characterize 
the subdomains that are responsible for BCRP oligomerization and explore 
possible mechanisms.  
In the present studies, we dissected TM5-ECL3-TM6 into three distinct 
domains, including ECL3, TM5 and TM6, to investigate the contribution of each 
domain to the oligomerization and functions of BCRP. We engineered several 
domain-swapping constructs (Figure 5A, 6A, 7A) by substituting ECL3, TM5 or 
TM6 with ECL1, TM1 or TM2, respectively. We chose this domain-swapping 
design because the truncated construct Myc-BCRPTM12 has neither the ability to 
interact with full-length BCRP nor the oligomerization activity by itself in living cells 
(Xu et al., 2007), indicating that TM1 or TM2 is not important for the 
oligomerization activity of BCRP; therefore, replacing TM5/ECL3/TM6 with 
TM1/ECL1/TM2 is less possible to promote artificial domain interactions or to 
complicate the formation of BCRP oligomers. In addition, we also compared the 
estimated hydrophobicity of each TM domain (Table 5) to investigate the 
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involvement of hydrophobic interactions in the oligomerization of BCRP. We have 
demonstrated that Myc-BCRPFL-TM5TM6 (Figure 6) interacts with full-length BCRP 
at a similar level to wild-type BCRP, while Myc-BCRPFL-TM6 (Figure 7) showed a 
decreased ability to interact with full-length BCRP. Since substitution of TM5 by 
TM1 does not change the hydrophobicity between Myc-BCRPFL-TM5TM6 and 
Myc-BCRPFL-TM6, other protein-protein interactions possibly account for the 
oligomerization activity mediated by TM5. Moreover, we have also shown that 
Myc-BCRPFL-TM5 (Figure 7) has a markedly decreased ability to interact with 
full-length BCRP compared to Myc-BCRPFL-TM5TM6 and replacement of TM6 by 
TM2 greatly reduced the hydrophobicity of Myc-BCRPFL-TM5 (Table 5). This 
observation may indicate that one of the major factors of TM6 contributing to 
BCRP oligomerization is due to its hydrophobicity.  
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Table 5: The GRAVY score of TM domains of BCRP for engineering 
domain-swapping full-length BCRP constructs. 
TM domain No. of aa Amino acids sequence GRAVY score 
TM1 21 IAQIIVTVVLGLVIGAIYFGL 2.400 
TM5 21 VATLLMTICFVFMMIFSGLLV 2.505 
TM2 20 LFFLTTNQCFSSVSAVELFV 1.260 
TM6 21 VALACMIVIFLTIAYLKLLFL 2.581 
Grand average of hydropathicity (GRAVY: indicates the solubility of the proteins: 
positive GRAVY (hydrophobic), negative GRAVY (hydrophilic) (Kyte and Doolittle, 
1982) (http://www.expasy.ch/tools/protparam.html). 
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ECL3 appears to be an essential domain for BCRP oligomerization (Figure 
4B and Figure 5B). However, neither the three cysteines nor the 569QYFS motif 
are necessary for the interaction between Myc-BCRPFL-ECL3 and full-length BCRP 
(Figure 5B) or the oligomerization activity of ECL3 by itself in living cells (Figure 
8B). Among the three cysteines predicted on the extracellular face of BCRP, 
Cys603 might be involved in the formation of an intermolecular disulfide bond, 
while Cy592 and Cy608 are responsible for the formation of an intramolecular 
disulfide bond within ECL3 of BCRP (Wakabayashi et al., 2006). In order to 
investigate the functional relevance of cysteines in BCRP, Liu et al. created a 
series of cysless mutants and expressed them in Sf9 insect cells (Liu et al., 2008). 
The results demonstrated that Cys592, Cys603 and Cys608 in ECL3 are not 
important for either expression or function of BCRP expressed in insect cells. 
Additionally, a recent study using fluorescence resonance energy transfer (FRET) 
analysis has also demonstrated that Cys603Ala mutant of BCRP does not affect 
the dimer/oligomer formation of BCRP in vivo (Ni et al., 2010). Therefore, our 
results are consistent with the above observation that Cys592, Cys603 and 
Cys608 are not essential for BCRP oligomerization. 
The short polar motif QXXS was first identified in the bacterial Tar-1 
homodimer TM domain and has been found sufficient to induce stable TM-TM 
interactions (Sal-Man et al., 2004). The two polar residues (Q and S) are crucial 
for the dimerization of the Tar-1 TM domain in vivo by creating symmetric 
hydrogen bonds that promote and/or stabilize the dimeric state of Tar-1. 
Replacement of these two polar residues by nonpolar residues markedly impaired 
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the self-association ability of the TM domain. The QXXS motif is commonly 
present in a bacterial TM database, suggesting a general role for this motif in TM 
assembly (Sal-Man et al., 2005). In our studies, we replaced these two polar 
residues with the nonpolar residue alanine to disrupt the potential inter-helical 
hydrogen bond formation. However, results from both the co-immunoprecipitation 
and the chemical cross-linking studies suggest that the 569QXXS motif is not 
essential for the formation of BCRP oligomer. This result could possibly be 
explained by the fact that the putative 569QXXS motif is located in the extracellular 
loop of BCRP, instead of transmembrane domains, therefore losing the ability to 
promote hydrogen bond formation and dimer formation. In conclusion, ECL3 is an 
essential element in BCRP oligomerization, and the detailed mechanisms of 
interactions need to be further explored.  
Chemical cross-linking, a biochemical approach used in our studies,  
takes advantage of specific features of various cross-linkers and provides 
covalent binding among adjacent subunits in a protein complex in living cells, 
which allows the detection of the cross-linked complex on SDS-PAGE for size 
estimation (Das and Fox, 1979). The results of chemical cross-linking are largely 
dependent on the distance between active groups and concentrations of the 
cross-linker as well as the availability of adjacent reactive groups in the 
neighboring protein subunits of a complex. DSS, a noncleavable and membrane 
permeable crosslinker that reacts with primary amines, has a spacer arm length of 
11.4Å, which is within the intermolecular distance of BCRP obtained from purified 
protein studies (McDevitt et al., 2006, Dezi et al., 2010) and therefore is able to 
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detect possible interactions between the transmembrane domains and the 
extracellular loop of BCRP. Indeed, Myc-BCRPFLWT showed four major bands 
corresponding to tetramer, trimer, dimer and monomer, with less than 50% of 
BCRP monomers cross-linked (Xu et al., 2004). In contrast, most of the 
domain-swapping mutants in our studies displayed higher cross-linking efficiency, 
suggesting that domain-swapping might affect the conformation of the resulting 
proteins, therefore possibly increasing the proximity of the interacting subdomains 
and increasing cross-linking of higher forms. Nevertheless, oligomers higher than 
tetramer could not be detected for both wild-type and mutant BCRP, consistent 
with our previous findings (Xu et al., 2004). 
Two anticancer agents used in our functional studies are mitoxantrone and 
Adriamycin. Mitoxantrone is a type II topoisomerase inhibitor, which disrupts DNA 
synthesis and DNA repair by intercalating into DNA. Selection with mitoxantrone 
usually results in overexpression of BCRP, and resistance to mitoxantrone is the 
most distinctive feature of the phenotype conferred by BCRP. On the other hand, 
Adriamycin, also called doxorubicin, is an anthracycline antibiotic, and its 
cytotoxicity is mainly mediated by inhibiting topoisomerase II, intercalating DNA 
and inducing reactive oxygen species production. All our BCRP constructs harbor 
482T mutations, therefore maintaining the ability to transport both mitoxantrone 
and Adriamycin effectively. So far, the exact binding sites of mitoxantrone or 
Adriamycin on BCRP are not clear, which creats some uncertainty in explaining 
the altered transport activity and resistance phenotype of BCRP 
domain-swapping constructs. However, early studies have suggested that the 
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interactions of substrate with BCRP involve multiple binding sites in the protein 
(Giri et al., 2009). Moreover, at least one amino acid, H630 (Miwa et al., 2003), 
which is predicted to be close to or in TM6, has been shown to be associated with 
mitoxantrone and Adriamycin recognition. Nevertheless, a recent study using 
purified ECL3 peptide has demonstrated that ECL3 constitutes a 
porphyrin-binding domain interacting with heme, but it does not bind to 
mitoxantrone or doxorubicin (Desuzinges-Mandon et al., 2010). Therefore, the 
loss of transport function of Myc-BCRPFL-TM6 is possibly not attributed to loss of 
substrate binding, and the observation that Myc-BCRPFL-ECL3 does not retain 
BCRP transport activity might be partially related to loss of substrate binding, 
given that TM6 might be crucial for recognition of mitoxantrone or Adriamycin. 
TM5, but not TM6 or ECL3, has been shown in our studies to be a major 
contributor to transport activity and resistance mediated by BCRP. This is 
consistent with previous reports that TM5 contains several amino acids that are 
essential for the membrane trafficking and transport activity of BCRP. Kage et al. 
have found that a leucine to proline mutation at residue 554 in the putative TM5 of 
BCRP could partially reverse the resistance of wild-type BCRP to SN-38 and 
mitoxantrone, indicating L554 might be important for transport activity (Kage et al., 
2002). Moreover, N557 might play an important role in the proper routing of BCRP 
(Mohrmann et al., 2005). One conserved residue G553 in TM5, the corresponding 
residue of which is involved in the dimerization of the Drosophila white protein 
(Mackenzie et al., 1999), has been examined as well. G553 does not seem to 
contribute to the formation of BCRP dimer/oligomer; instead, G553L mutant 
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reduced protein expression and abolished N-glysosylation and the membrane 
trafficking of BCRP (Polgar et al., 2006). In addition, a steroid binding element has 
recently been found in TM5 (Velamakanni et al., 2008), further verifying the 
signifance of TM5 in substrate binding of BCRP. These data suggest that TM5 
harbors several amino acids or elements that are important for the substrate 
binding, membrane trafficking and transport activity of BCRP, which is consistent 
with our findings that TM5 is a major contributor to BCRP functions. 
Based on the quantification analyses of our co-immunoprecipitation results, 
it has been shown that the oligomerization activity of BCRP is mediated by ECL3, 
TM5 and TM6, while each domain contributes partially to form the oligomeric 
BCRP complex. Nevertheless, both drug resistance assays and the drug 
accumulation assay have shown that Myc-BCRPFL-TM5 retains BCRP functions, 
while Myc-BCRPFL-ECL3TM6, a construct without TM5, totally lost BCRP activities. 
Furthermore, I also showed that both Myc-BCRPFL-ECL3 and Myc-BCRPFL-TM6 lost 
BCRP functions, while their counterparts Myc-BCRPFL-TM5TM6 or 
Myc-BCRPFL-TM5ECL3, which have been assisted by the existence of TM5, 
recovered both drug efflux of and drug resistance mediated by BCRP. These 
results suggest that the oligomerization activity of BCRP, at least the part 
mediated by ECL3 or TM6, is not directly correlated with the functions of BCRP. 
The existence of BCRP oligomers might provide another level of regulation 
for this drug resistance transporter (Mo and Zhang, 2009). One possibility is that 
different oligomeric states may be coupled with the catalytic cycle and promote 
transporter activity. In the nucleotide-free state, BCRP may exist as low 
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oligomerization state such as monomer. ATP/substrate binding would trigger 
conformational changes that bring the adjacent transporters closer and induce the 
formation of higher order oligomers. This oligomer formation would create a 
complex with a larger central pore, allowing a higher degree of substrate 
transport. Following completion of the transport process with ATP hydrolysis, the 
conformation of the ABC transporter restores, and oligomers dissociate. Another 
possibility is that the formation of dimers or higher order oligomers may simply 
play a regulatory role either as a functional unit or reservoir of non-functional 
molecules waiting to be activated for function. The finding that monomeric and 
dimeric ABCB1 tend to have a higher degree of phosphorylation compared to 
higher order oligomeric ABCB1 (Poruchynsky and Ling, 1994) suggests that 
post-translational modifications may regulate this activation/inactivation process. 
Given that co-expression of protein kinase C could promote substrate binding and 
ATPase activity of ABCB1 (Ahmad et al., 1994), phosphorylation may activate 
dissociation of the oligomeric ABCB1. In contrast, disruption of phosphorylation of 
BCRP resulted in impaired plasma membrane trafficking and reduced 
oligomerization, indicating that the oligomerization of BCRP probably happens on 
the plasma membrane; therefore, reduction in the amount of protein trafficked to 
the membrane leads to less formation of BCRP oligomers.  
As the number of documented oligomerization of ABC transporters rapidly 
grows (see (Mo and Zhang, 2009) for comprehensive review), it is important to 
understand the functional significance of these complexes. Studies of G-protein 
coupled receptor oligomerization have brought advances in technology to clarify 
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the composition, plasma membrane targeting, and function of oligomeric protein 
complexes (Gurevich and Gurevich, 2008). For example, FRET experiments 
could be used to track protein-protein interactions in time and space, while 
Bioluminescence resonance energy transfer (BRET) assays could be used to 
measure the relative affinities of protein-protein interactions. Moreover, a variety 
of computational studies based on sequence analysis and docking experiments 
have been performed towards the understanding of membrane protein 
complexes’ structures (Simpson et al.). Indeed, Ni et al. have applied FRET assay 
to wild-type BCRP and directly demonstrated that BCRP could form 
dimer/oligomer in cellular levels (Ni et al., 2010). This result provides a basis for 
further applying new technologies to investigate the oligomerization and function 
of BCRP and related ABC transporters.  
In conclusion, we have demonstrated in our studies that ECL3, TM5 and 
TM6 all play a partial role in BCRP oligomerization, while only TM5 is a key 
element for BCRP function. These findings suggest that oligomerization of BCRP 
might not be directly required for transport or resistance phenotype mediated by 
BCRP. Instead, BCRP might work as a monomer, while the existence of BCRP 
oligomers on the plasma membrane is a form of regulation, as discussed above. 
Still, the physiological and pharmacological significance of BCRP oligomers 
remains to be fully elucidated. 
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V. Summary and conclusion 
The experimental results of this dissertation can be summarized as follows: 
1. ECL3, TM5 and TM6 all play a partial role in BCRP oligomerization, 
and each domain might contain at least one interacting site responsible for the 
formation of oligomeric BCRP.  
2. The oligomerization activity of BCRP is partially mediated by ECL3. 
Nevertheless, disruption of this oligomerizaition mediated by ECL3 does not 
significantly affect the drug transport activity of or drug resistance conferred by 
BCRP. 
3. TM5 plays a less important role in the formation of BCRP oligomers. 
However, TM5 is a major contributor of the drug transport activity of or drug 
resistance conferred by BCRP. 
4. TM6 also contributes in part to BCRP oligomerization. Meanwhile, 
this domain is also not essential for BCRP functions. 
5. The findings of the relationship between BCRP oligomerization and 
function have enriched our understanding of the structure-function relationship of 
BCRP and will help to set the basis for the development of a better 
chemosensitizing regimen targeting BCRP-mediated MDR in cancer 
chemotherapies in the future.  
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VI. Future plans 
Based on the present work, we conclude that ECL3, TM5 and TM6 all play 
a partial role in BCRP oligomerization, while only TM5 is a key element for the 
drug transport of and drug resistance mediated by BCRP. Future directions that 
may extend the current work are: 
1. To further determine via alanine scanning assays which amino acids 
in ECL3, TM5 and TM6 are crucial for the oligomerization of BCRP. 
2. To verify via FRET analysis whether the domain-swapping 
constructs of BCRP do form oligomers in intact cells. 
3. To characterize via FRET experiments the oligomer formation of 
BCRP and its domain-swapping constructs at tissue level. 
4. To identify the cellular compartment(s) where BCRP assembles into 
higher order oligomers. 
5. To further identify the contribution of TM5 to the drug binding and 
ATPase activity of BCRP. 
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